

Bostel Tilman, Akbaba Sati, Wollschlaeger Daniel, Mayer Arnulf, Nikolaidou Eirini, Murnik Markus, Kirste Simon, Ruehle Alexander, Grosu Anca-Ligia, Debus Juergen, Fottner Christian, Moehler Markus, Grimminger Peter, Schmidberger Heinz, Nicolay Nils Henrik
Chemoradiotherapy in geriatric patients with squamous cell carcinoma of the esophagus: Multi-center analysis on the value of standard treatment in the elderly
FRONTIERS IN ONCOLOGY. 2023; 13. Article

Delic Maike, Boeswald Veronika, Goepfert Katrin, Pabst Petra, Moehler Markus
In vitro Characterization of Enhanced Human Immune Responses by GM-CSF Encoding HSV-1-Induced Melanoma Cells
ONCOTARGETS AND THERAPY. 2022; 15: 1291-1307. Article

Fottner C., Silber M., Bergholz L., Gartenschlaeger J., Gans R., Ferrata M., Zimmermann A., Gartenschlaeger M., Bostel T., Moehler M., Grimminger P., Weber M. M.
Effect of a standardized nutritional support program on nutritional status, body composition, morbidity and mortality in patients with advanced upper gastrointestinal (UGI) cancer before and after neo-adjuvant radiochemotherapy followed by surgery
ANNALS OF ONCOLOGY. 2022; 33(7): S1114-S1115. Meeting Abstract

Gerber Tiemo S., Mueller Lukas, Bartsch Fabian, Groger Lisa-Katharina, Schindeldecker Mario, Ridder Dirk A., Goepfert Benjamin, Moehler Markus, Dueber Christoph, Lang Hauke, Roth Wilfried, Kloeckner Roman, Straub Beate K.
Integrative Analysis of Intrahepatic Cholangiocarcinoma Subtypes for Improved Patient Stratification: Clinical, Pathological, and Radiological Considerations
CANCERS. 2022; 14(13). Article

Hoegner Anica, Moehler Markus
Immunotherapy in Gastric Cancer
CURRENT ONCOLOGY. 2022; 29(3): 1559-1574. Article

Hofmann Felix O., Heinemann Volker, D'Anastasi Melvin, Gesenhues Alena B., Hesse Nina, von Weikersthal Ludwig Fischer, Decker Thomas, Kiani Alexander, Moehler Markus, Kaiser Florian, Heintges Tobias, Kahl Christoph, Kullmann Frank, Scheithauer Werner, Link Hartmut, Modest Dominik P., Stintzing Sebastian, Holch Julian W.
Standard diametric versus volumetric early tumor shrinkage as a predictor of survival in metastatic colorectal cancer: subgroup findings of the randomized, open-label phase III trial FIRE-3/AIO KRK-0306
EUROPEAN RADIOLOGY. 2022; 33(2): 1174-1184. Article

Huber Yvonne, Foerster Friedrich, Moehler Markus, Galle Peter R.
New Studies at the University Medical Center Mainz on HCC and non-metastatic Colon Carcinoma
GASTROENTEROLOGIE. 2022; 17(1): 57-58. Editorial Material

Kaps Leonard, Omogbehin Lea, Hildebrand Katharina, Gairing Simon J., Schleicher Eva M., Moehler Markus, Rahman Fareed, Schattenberg Joern M., Woerns Marcus-Alexander, Galle Peter R., Labenz Christian
Health literacy in gastrointestinal diseases: a comparative analysis between patients with liver cirrhosis, inflammatory bowel disease and gastrointestinal cancer
SCIENTIFIC REPORTS. 2022; 12(1). Article

Kroese Tiuri E., van Hillegersberg Richard, Schoppmann Sebastian, Deseyne Pieter R. A. J., Nafteux Philippe, Obermannova Radka, Nordmark Marianne, Pfeiffer Per, Hawkins Maria A., Smyth Elizabeth, Markar Sheraz, Hanna George B., Cheong Edward, Chaudry Asif, Elme Anneli, Adenis Antoine, Piessen Guillaume, Gani Cihan, Bruns Christiane J., Moehler Markus, Liakakos Theodore, Reynolds John, Morganti Alessio, Rosati Riccardo, Castoro Carlo, D'Ugo Domenico, Roviello Franco, Bencivenga Maria, de Manzoni Giovanni, Jeene Paul, van Sandick Johanna W., Muijs Christel, Slingerland Marije, Nieuwenhuijzen Grard, Wijnhoven Bas, Beerepoot ?, Kolodziejczyk Piotr, Polkowski Wojciech P., Alsina Maria, Pera Manuel, Kanonnikoff Tania F., Nilsson Magnus, Guckenberger Matthias, Monig Stefan, Wagner Dorethea, Wyrwicz Lucjan, Berbee Maaïke, Gockel Ines, Lordick Florian, Griffiths Ewen A., Verheij Marcel, van Rossum Peter S. N., van Laarhoven Hanneke W. M.

Definitions and treatment of oligometastatic oesophagogastric cancer according to multidisciplinary tumour boards in Europe

EUROPEAN JOURNAL OF CANCER. 2022; 164: 18-29. Article

Ledenko Matthew, Antwi Samuel O., Arima Shiho, Driscoll Julia, Furuse Junji, Klumpen Heinz-Josef, Larsen Finn Ole, Lau David K., Maderer Annett, Markussen Alice, Moehler Markus, Nooijen Lynn E., Shaib Walid L., Tebbutt Niall C., Andre Thierry, Ueno Makoto, Woodford Rachel, Yoo Changhoon, Zalupski Mark M., Patel Tushar

Sex-related disparities in outcomes of cholangiocarcinoma patients in treatment trials

FRONTIERS IN ONCOLOGY. 2022; 12. Review

Lederer Ann-Kathrin, Bartsch Fabian, Moehler Markus, Gassmann Peter, Lang Hauke
Morbidity and Mortality of Neutropenic Patients in Visceral Surgery: A Narrative Review
CELLS. 2022; 11(20). Review

Lei Ming, Janjigian Yelena Y., Ajani Jaffer A., Moehler Markus, Wang Xuya, Shen Lin, Garrido Marcelo, Gallardo Carlos, Yamaguchi Kensei, Wyrwicz Lucjan, Skoczylas Tomasz, Bragagnoli Arinilda, Liu Tianshu, Tehfe Mustapha, Elimova Elena, Li Mingshun, Poulart Valerie, Wang Yu, Doshi Parul, Shitara Kohei

Nivolumab (NIVO) plus chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC):

CheckMate 649 biomarker analyses

CANCER RESEARCH. 2022; 82(12). Meeting Abstract

Liu Lian, Erickson Nicole Tonya, Ricard Ingrid, von Weikersthal Ludwig Fischer, Lerch Markus M., Decker Thomas, Kiani Alexander, Kaiser Florian, Heintges Tobias, Kahl Christoph, Kullmann Frank, Scheithauer Werner, Link Hartmut, Hoeffkes Heinz-Gert, Moehler Markus, Gesenhues Alena Britta, Theurich Sebastian, Michl Marlies, Modest Dominik P., Alguel Hana, Stintzing Sebastian, Heinemann Volker, Holch Julian W.

Early weight loss is an independent risk factor for shorter survival and increased side effects in patients with metastatic colorectal cancer undergoing first-line treatment within the randomized Phase III trial FIRE-3 (AIO KRK-0306)

INTERNATIONAL JOURNAL OF CANCER. 2022; 150(1): 112-123. Article

Liu Lian, Erickson Nicole Tonya, Ricard Ingrid, von Weikersthal Ludwig Fischer, Lerch Markus M., Decker Thomas, Kiani Alexander, Kaiser Florian, Heintges Tobias, Kahl Christoph, Kullmann Frank, Scheithauer Werner, Link Hartmut, Hoffkes Heinz-Gert, Moehler Markus, Gesenhues Alena Britta,

Theurich Sebastian, Michl Marlies, Modest Dominik P., Algul Hana, Stintzing Sebastian, Heinemann Volker, Holch Julian W.

Early weight loss is an independent risk factor for shorter survival and increased side effects in patients with metastatic colorectal cancer under-going first-line treatment within the randomized Phase III trial FIRE-3 (AIO KRK-0306) (vol 150, pg 112, 2022)

INTERNATIONAL JOURNAL OF CANCER. 2022; 150(9): E5-E5. Correction

Lorenzen Sylvie, Stocker Gertraud, Moehler Markus, Goetze Thorsten Oliver, Stein Alexander, Goekkurt Eray, Haag Georg Martin, Albatran Salah-E, Hofheinz Ralf, Homann Nils, Schmalenberg Harald, Stahl Michael K., Heinrich Kathrin, Moenig Stefan, Thuss-Patience Peter

Studies of the oesophageal and gastric cancer working group of the Arbeitsgemeinschaft Internistische Onkologie (AIO)

ONKOLOGE. 2022; 28(SUPPL 1): 23-29. Article

McNamara Mairead G., Bridgewater John, Goyal Lipika, Jacobs Timothy, Wagner Anna D., Goldstein David, Shroff Rachna, Moehler Markus, Lowery Maeve, Bekaii-Saab Tanios, Kelley Robin K., Furuse Junji, Rimassa Lorenza, Morizane Chigusa, Lamarca Angela, Hubner Richard, Knox Jennifer, Valle Juan
What is the gender representation in authorship in later phase systemic clinical trials in biliary tract cancer (BTC)?-a retrospective review of the published literature

BMJ OPEN. 2022; 12(10). Review

Moehler Markus, Hoegner Anica, Wagner Anna D., Obermannova Radka, Alsina Maria, Thuss-Patience Peter, van Laarhoven Hanneke, Smyth Elizabeth

Recent progress and current challenges of immunotherapy in advanced/metastatic esophagogastric adenocarcinoma

EUROPEAN JOURNAL OF CANCER. 2022; 176: 13-29. Article

Moehler Ricarda, Jenetzky Ekkehart, Schwarz Silke, Gwiasda Moritz, Rathjens Larisa, Szoke Henrik, Martin David

Parental Confidence in Relation to Antipyretic Use, Warning Signs, Symptoms and Well-Being in Fever Management-Results from an App-Based Registry

INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH. 2022; 19(21). Article

Pape Marieke, Vissers Pauline A. J., Beerepoot ?, Henegouwen Mark I. van Berge, Lagarde Sjoerd M., Mook Stella, Moehler Markus, van Laarhoven Hanneke W. M., Verhoeven Rob H. A.

A population-based study in resected esophageal or gastroesophageal junction cancer aligned with CheckMate 577

THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY. 2022; 14. Article

Pavlakis Nick, Shitara Kohei, Sjoquist Katrin Marie, Martin Andrew James, Jaworski Anthony, Yip Sonia, Oh Do-Youn, Moehler Markus H., Bekaii-Saab Tanios S., Simes John, Goldstein David

INTEGRATE IIb: A randomized phase III open label study of regorafenib plus nivolumab versus standard chemotherapy in refractory advanced gastroesophageal cancer (AGOC)

JOURNAL OF CLINICAL ONCOLOGY. 2022; 40(4). Meeting Abstract

Scherrer Alexander, Zimmermann Tobias, Riedel Sinan, Mousa Fihmi, Wasswa-Musisi Isa, Zifrid Robert, Tillil Hartmut, Ulrich Philip, Kosmidis Thanos, Reis Joaquim, Oestreicher Gabrielle, Moehler Markus, Kalamaras Ilias, Votis Konstantinos, Venios Stefanos, Plakia Maria, Diamantopoulos Sotiris

Digitally Assisted Planning and Monitoring of Supportive Recommendations in Cancer Patients
IFIP Advances in Information and Communication Technology. 2022; 652: 401-411. Proceedings
Paper

Shitara Kohei, Ajani Jaffer A., Moehler Markus, Garrido Marcelo, Gallardo Carlos, Shen Lin,
Yamaguchi Kensei, Wyrwicz Lucjan, Skoczylas Tomasz, Bragagnoli Arinilda Campos, Liu Tianshu, Tehfe
Mustapha, Elimova Elena, Bruges Ricardo, Zander Thomas, de Azevedo Sergio, Kowalyszyn Ruben,
Pazo-Cid Roberto, Schenker Michael, Cleary James M., Yanez Patricio, Feeney Kynan, Karamouzis ?,
Poulart Valerie, Lei Ming, Xiao Hong, Kondo Kaoru, Li Mingshun, Janjigian Yelena Y.
Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer
NATURE. 2022; 603(7903): 942-+. Article

Shitara Kohei, Janjigian Yelena Y., Moehler Markus H., Garrido Marcelo, Gallardo Carlos, Shen Lin,
Yamaguchi Kensei, Wyrwicz Lucjan, Skoczylas Tomasz, Silva Arinilda, Bragagnoli Campos, Liu Tianshu,
Tehfe Mustapha, Elimova Elena, Soleymani Samira, Lei Ming, Kondo Kaoru, Li Mingshun, Ajani Jaffer
A.

Nivolumab (NIVO) plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for
advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma
(GC/GEJC/EAC): Expanded efficacy, safety, and subgroup analyses from CheckMate 649
JOURNAL OF CLINICAL ONCOLOGY. 2022; 40(4). Meeting Abstract

Sivanathan Visvakanth, Utz Christoph, Thomaidis Thomas, Foerster Friedrich, Stahl Michael, Lordick
Florian, Ibach Stefan, Kanzler Stephan, Adler Andreas, Moenig Stefan Paul, Schimanski Carl C., Ignee
Andre, Dietrich Christoph F., Galle Peter R., Moehler Markus
Predictive Value of Preoperative Endoscopic Ultrasound (EUS) After Neoadjuvant Chemotherapy in
Locally Advanced Esophagogastric Cancer - Data From a Randomized German Phase II Trial
ULTRASCHALL IN DER MEDIZIN. 2022; 43(05): 514-521. Article

Stahler Arndt, Stintzing Sebastian, von Einem Jobst C., Westphalen (Benedikt) Christoph B., Heinrich
Kathrin, Kraemer Nicole, Michl Marlies, Modest Dominik P., von Weikersthal Ludwig Fischer, Decker
Thomas, Kiani Alexander, Heintges Tobias, Kahl Christoph, Kullmann Frank, Scheithauer Werner,
Moehler Markus, Kaiser Florian, Kirchner Thomas, Jung Andreas, Heinemann Volker
Single-nucleotide variants, tumour mutational burden and microsatellite instability in patients with
metastatic colorectal cancer: Next-generation sequencing results of the FIRE-3 trial (vol 137, pg 250,
2020)
EUROPEAN JOURNAL OF CANCER. 2022; 169: 223-225. Correction

Stolze T., Franke S., Haybaeck J., Moehler M., Grimminger P. P., Lang H., Roth W., Gockel I, Kreuser
N., Blaker H., Wittekind C., Lordick F., Vieth M., Veits L., Waidmann O., Lingohr P., Peitz U., Schildberg
C., Kruschewski M., Vassos N., Goni E., Bruns C. J., Ridwelski K., Wolff S., Lippert H., Schumacher J.,
Malfertheiner P., Venerito M.
Mismatch repair deficiency, chemotherapy and survival for resectable gastric cancer: an
observational study from the German staR cohort and a meta-analysis
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY. 2022. Article

Thol Felix, Gairing Simon Johannes, Czauderna Carolin, Thomaidis Thomas, Gamstatter Thomas,
Huber Yvonne, Vollmar Johanna, Lorenz Johanna, Michel Maurice, Bartsch Fabian, Muller Lukas,
Kloeckner Roman, Galle Peter Robert, Worns Marcus-Alexander, Marquardt Jens Uwe, Moehler
Markus, Weinmann Arndt, Foerster Friedrich

Outcomes in patients receiving palliative chemotherapy for advanced biliary tract cancer
JHEP REPORTS. 2022; 4(3). Article

Unterrainer Marcus, Deroose Christophe M., Herrmann Ken, Moehler Markus, Blomqvist Lennart, Cannella Roberto, Caramella Caroline, Caruso Damiano, Chouhan Manil D., Denecke Timm, De la Pinta Carolina, De Geus-Oei Lioe-Fee, Dulskas Audrius, Eisenblatter Michel, Foley Kieran G., Gourtsoyianni Sofia, Lecouvet Frederic E., Lopci Egesta, Maas Monique, Obmann Markus M., Oprea-Lager Daniela E., Verhoeff Joost J. C., Santiago Ines, Terraz Sylvain, D'Anastasi Melvin, Regge Daniele, Laghi Andrea, Beets-Tan Regina G. H., Heinemann Volker, Lordick Florian, Smyth Elizabeth C., Ricke Jens, Kunz Wolfgang G.

Imaging standardisation in metastatic colorectal cancer: A joint EORTC-ESOI-ESGAR expert consensus recommendation

EUROPEAN JOURNAL OF CANCER. 2022; 176: 193-206. Article

Wainberg Zev A., Van Cutsem Eric, Moehler Markus H., Kang Yoon-Koo, Yen Priscilla, Finger Elizabeth, Keegan Alissa, Shitara Kohei

Trial in progress: Phase 1b/3 study of bemarituzumab+mFOLFOX6+nivolumab versus mFOLFOX6+nivolumab in previously untreated advanced gastric and gastroesophageal junction (GEJ) cancer with FGFR2b overexpression (FORTITUDE-102)

JOURNAL OF CLINICAL ONCOLOGY. 2022; 40(16). Meeting Abstract

Yoon Harry H., Jin Zhaohui, Kour Oudom, Fonkoua Lionel Aurelien Kankeu, Shitara Kohei, Gibson Michael K., Prokop Larry J., Moehler Markus, Kang Yoon-Koo, Shi Qian, Ajani Jaffer A.

Association of PD-L1 Expression and Other Variables With Benefit From Immune Checkpoint Inhibition in Advanced Gastroesophageal Cancer Systematic Review and Meta-analysis of 17 Phase 3 Randomized Clinical Trials

JAMA ONCOLOGY. 2022; 8(10): 1456-1465. Review

Yoon Harry H., Jin Zhaohui, Kour Oudom, Fonkoua Lionel Aurelien Kankeu, Shitara Kohei, Gibson Michael K., Prokop Larry J., Moehler Markus, Kang Yoon-Koo, Shi Qian, Ajani Jaffer A.

Association of PD-L1 Expression and Other Variables With Benefit From Immune Checkpoint Inhibition in Advanced Gastroesophageal Cancer Systematic Review and Meta-analysis of 17 Phase 3 Randomized Clinical Trials

JAMA ONCOLOGY. 2022. Review

Catenacci D., Rosales M. Koshiji, Chung H., Yoon H., Moehler M., Kang Y., Shen L.

Margetuximab combined with anti-PD-1 (retifanlimab) or anti-PD-1/LAG-3 (tebotelimab) plus /- chemotherapy in first-line therapy of advanced/metastatic HER2+gastroesophageal junction or gastric cancer

ANNALS OF ONCOLOGY. 2021; 32: S146-S146. Meeting Abstract

Catenacci Daniel V. T., Rosales Minori, Chung Hyun Cheol, Yoon Harry H., Shen Lin, Moehler Markus, Kang Yoon-Koo

MAHOGANY: margetuximab combination in HER2(+) unresectable/metastatic gastric/gastroesophageal junction adenocarcinoma

FUTURE ONCOLOGY. 2021; 17(10): 1155-1164. Review

Catenacci Daniel V. T., Rosales Minori Koshiji, Chung Hyun Cheol, Yoon Harry H., Shen Lin, Moehler Markus H., Kang Yoon-Koo

Margetuximab (M) combined with anti-PD-1 (retifanlimab) or anti-PD-1/LAG-3 (tebotelimab) plus +/- chemotherapy (CTX) in first-line therapy of advanced/metastatic HER2+gastroesophageal junction (GEJ) or gastric cancer (GC).

JOURNAL OF CLINICAL ONCOLOGY. 2021; 39(3). Meeting Abstract

Elimova Elena, Wyrwicz Lucjan, Blum Steven I., Xiao Hong, Li Mingshun, Kondo Kaoru, Davenport Eric, Wang Jinyi, Hunter Shannon, Moehler Markus H.

Health-related quality of life (HRQOL) in patients (pts) with advanced gastric cancer/gastroesophageal junction cancer (GC/GEJC) or esophageal adenocarcinoma (EAC): Results of nivolumab plus chemotherapy (NIVO plus chemo) versus chemo from CheckMate 649

JOURNAL OF CLINICAL ONCOLOGY. 2021; 39(28). Meeting Abstract

Fontana Elisa, Meyers Jeff, Sobrero Alberto, Iveson Timothy, Shields Anthony F., Taieb Julien, Yoshino Takayuki, Souglakos Ioannis, Smyth Elizabeth C., Lordick Florian, Moehler Markus, Giraut Anne, Harkin Andrea, Labianca Roberto, Meyerhardt Jeffrey, Andre Thierry, Boukovinas Ioannis, Lonardi Sara, Saunders Mark, Vernerey Dewi, Oki Eiji, Georgoulis Vassilis, Ben-Aharon Irit, Shi Qian
Early-Onset Colorectal Adenocarcinoma in the IDEA Database: Treatment Adherence, Toxicities, and Outcomes With 3 and 6 Months of Adjuvant Fluoropyrimidine and Oxaliplatin

JOURNAL OF CLINICAL ONCOLOGY. 2021; 39(36): 4009-+. Article

Fontana Elisa, Meyers Jeffrey P., Sobrero Alberto F., Iveson Timothy, Shields Anthony Frank, Taieb Julien, Yoshino Takayuki, Souglakos Ioannis, Smyth Elizabeth Catherine, Lordick Florian, Moehler Markus H., Harkin Andrea, Labianca Roberto, Meyerhardt Jeffrey A., Andre Thierry, Yamanaka Takeharu, Boukovinas Ioannis, Grothey Axel, Ben-Aharon Irit, Shi Qian

Early-onset stage II/III colorectal adenocarcinoma in the IDEA database: Treatment adherence, toxicities, and outcomes from adjuvant fluoropyrimidine and oxaliplatin.

JOURNAL OF CLINICAL ONCOLOGY. 2021; 39(15). Meeting Abstract

Franck Caspar, Zimmermann Nadja, Goni Elisabetta, Lippert Hans, Ridwelski Karsten, Kruschewski Martin, Kreuser Nicole, Lingohr Philipp, Schildberg Claus, Vassos Nikolaos, Waidmann Oliver, Peitz Ulrich, Lang Hauke, Grmminger Peter P., Bruns Christiane, Veits Lothar, Vieth Michael, Moehler Markus, Lordick Florian, Gockel Ines, Schumacher Johannes, Malferteiner Peter, Venerito Marino
Different Prevalence of Alarm, Dyspeptic and Reflux Symptoms in Patients with Cardia and Non-cardia Gastric Cancer

JOURNAL OF GASTROINTESTINAL AND LIVER DISEASES. 2021; 30(4): 431-437. Article

Gairing Simon Johannes, Thol Felix, Mueller Lukas, Hahn Felix, Thomaidis Thomas, Czauderna Carolin, Bartsch Fabian, Pitton Michael Bernhard, Marquardt Jens Uwe, Worns Marcus-Alexander, Galle Peter Robert, Moehler Markus, Weinmann Arndt, Kloeckner Roman, Foerster Friedrich

The Addition of Transarterial Chemoembolization to Palliative Chemotherapy Extends Survival in Intrahepatic Cholangiocarcinoma

JOURNAL OF CLINICAL MEDICINE. 2021; 10(12). Article

Haupts Anna, Vogel Anne, Foersch Sebastian, Hartmann Monika, Maderer Annett, Wachter Nicolas, Huber Tobias, Kneist Werner, Roth Wilfried, Lang Hauke, Moehler Markus, Hartmann Nils

Comparative analysis of nuclear and mitochondrial DNA from tissue and liquid biopsies of colorectal cancer patients

SCIENTIFIC REPORTS. 2021; 11(1). Article

Heinemann Volker, von Weikersthal Ludwig Fischer, Decker Thomas, Kiani Alexander, Kaiser Florian, Al-Batran Salah-Edin, Heintges Tobias, Lerchenmuller Christoph, Kahl Christoph, Seipelt Gernot, Kullmann Frank, Moehler Markus, Scheithauer Werner, Held Swantje, Miller-Phillips Lisa, Modest Dominik Paul, Jung Andreas, Kirchner Thomas, Stintzing Sebastian
FOLFIRI plus cetuximab or bevacizumab for advanced colorectal cancer: final survival and per-protocol analysis of FIRE-3, a randomised clinical trial
BRITISH JOURNAL OF CANCER. 2021; 124(3): 587-594. Article

Janjigian Y. Y., Ajani J. A., Moehler M., Garrido M., Gallardo C., Shen L., Yamaguchi K., Wyrwicz L., Skoczylas T., Bragagnoli A., Liu T., Tehfe M., Elimova E., Li M., Poulart V., Lei M., Kondo K., Shitara K.
Nivolumab (NIVO) plus chemotherapy (Chemo) or ipilimumab (IPI) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): CheckMate 649 study
ANNALS OF ONCOLOGY. 2021; 32: S1329-S1330. Meeting Abstract

Janjigian Yelena Y., Shitara Kohei, Moehler Markus, Garrido Marcelo, Salman Pamela, Shen Lin, Wyrwicz Lucjan, Yamaguchi Kensei, Skoczylas Tomasz, Bragagnoli Arinilda Campos, Liu Tianshu, Schenker Michael, Yanez Patricio, Tehfe Mustapha, Kowalyszyn Ruben, Karamouzis Michalis V., Bruges Ricardo, Zander Thomas, Pazo-Cid Roberto, Hitre Erika, Feeney Kynan, Cleary James M., Poulart Valerie, Cullen Dana, Lei Ming, Xiao Hong, Kondo Kaoru, Li Mingshun, Ajani Jaffer A.
First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial
LANCET. 2021; 398(10294): 27-40. Article

Kelly R. J., Ajani J., Kuzdzal J., Zander T., Van Cutsem E., Piessen G., Mendez G., Feliciano J., Motoyama S., Lievre A., Uronis H., Elimova E., Grootsholten C., Geboes K., Zhang J., Zhu L., Lei M., Kondo K., Cleary J. M., Moehler M.
Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer Following Neoadjuvant Chemoradiation Therapy: First Results of the CheckMate 577 Study
ANNALS OF SURGICAL ONCOLOGY. 2021; 28(SUPPL 1): S41-S42. Meeting Abstract

Kelly Ronan J., Ajani Jaffer A., Kuzdzal Jaroslaw, Zander Thomas, Van Cutsem Eric, Piessen Guillaume, Mendez Guillermo, Feliciano Josephine, Motoyama Satoru, Lievre Astrid, Uronis Hope, Elimova Elena, Grootsholten Cecile, Geboes Karen, Zafar Syed, Snow Stephanie, Ko Andrew H., Feeney Kynan, Schenker Michael, Kocon Piotr, Zhang Jenny, Zhu Lili, Lei Ming, Singh Prianka, Kondo Kaoru, Cleary James M., Moehler Markus
Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer
NEW ENGLAND JOURNAL OF MEDICINE. 2021; 384(13): 1191-1203. Article

Kelly Ronan Joseph, Ajani Jaffer A., Kuzdzal Jaroslaw, Zander Thomas, Van Cutsem Eric, Piessen Guillaume, Mendez Guillermo, Feliciano Josephine Louella, Motoyama Satoru, Lievre Astrid, Uronis Hope Elizabeth, Elimova Elena, Grootsholten Cecile, Geboes Karen Paula, Zhang Jenny, Soleymani Samira, Lei Ming, Singh Prianka, Cleary James M., Moehler Markus H.
Adjuvant nivolumab (NIVO) in resected esophageal or gastroesophageal junction cancer (EC/GEJC) following neoadjuvant chemoradiotherapy (CRT): Expanded efficacy and safety analyses from CheckMate 577.
JOURNAL OF CLINICAL ONCOLOGY. 2021; 39(15). Meeting Abstract

Koessler Thibaud, Alsina Maria, Arnold Dirk, Ben-Aharon Irit, Lutz Manfred P., Obermannova Radka, Peeters Mark, Sclafani Francesco, Smyth Elizabeth, Valle Juan W., Wagner Anna Dorothea, Wyrwicz Lucjan, Fontana Elisa, Moehler Markus

Highlights from ASCO-GI 2021 from EORTC Gastrointestinal tract cancer group
BRITISH JOURNAL OF CANCER. 2021; 125(7): 911-919. Article

Lang Hauke, Baumgart Janine, Roth Wilfried, Moehler Markus, Kloth Michael
Cancer gene related characterization of patterns and point of recurrence after resection of colorectal liver metastases

ANNALS OF TRANSLATIONAL MEDICINE. 2021; 9(17). Article

Lang Hauke, Kloth Michael, Moehler Markus, Roth Wilfried, Baumgart Janine
Response to the Comment on "Extended Molecular Profiling Improves Stratification and Prediction of Survival After Resection of Colorectal Liver Metastases"

ANNALS OF SURGERY. 2021; 274(6): E714-E714. Letter

Maderer Annett, Fiteni Frederic, Tanis Erik, Mauer Murielle, Schmitt Thomas, Aust Daniela E., Lutz Manfred P., Roelofson Felicitas, Gog Christiane, Weinmann Arndt, Koehne Claus H., Moehler Markus, Thomaidis Thomas

CXCR4 and hif-1 alpha as prognostic molecular markers for stage 3 colon cancer patients: post hoc analysis of the randomized, multicenter phase 3 PETACC-2 trial dataset

ACTA ONCOLOGICA. 2021; 60(11): 1543-1547. Letter

McNamara Mairead Geraldine, Bridgewater John A., Goyal Lipika, Goldstein David, Shroff Rachna T., Moehler Markus H., Lowery Maeve Aine, Bekaii-Saab Tanios S., Kelley Robin Kate, Furuse Junji, Rimassa Lorenza, Morizane Chigusa, Lamarca Angela, Hubner Richard, Knox Jennifer J., Valle Juan W.
Gender representation in authorship in later-phase systemic clinical trials in biliary tract cancer (BTC).
JOURNAL OF CLINICAL ONCOLOGY. 2021; 39(3). Meeting Abstract

Meric-Bernstam F., Furuse J., Oh D-Y., Bridgewater J. A., Goyal L., Bahleda R., Li K., Patel P., Soni N., Wacheck V., Moehler M.

Pooled analysis safety profile of futibatinib in patients with advanced solid tumors, including intrahepatic cholangiocarcinoma (iCCA)

ANNALS OF ONCOLOGY. 2021; 32: S378-S378. Meeting Abstract

Michel Maurice, Hess Cornelius, Kaps Leonard, Kremer Wolfgang M., Hilscher Max, Galle Peter R., Moehler Markus, Schattenberg Joern M., Woerns Marcus-Alexander, Labenz Christian, Nagel Michael
Elevated serum levels of methylglyoxal are associated with impaired liver function in patients with liver cirrhosis

SCIENTIFIC REPORTS. 2021; 11(1). Article

Michel Maurice, Kaps Leonard, Maderer Annett, Galle Peter R., Moehler Markus
The Role of p53 Dysfunction in Colorectal Cancer and Its Implication for Therapy
CANCERS. 2021; 13(10). Review

Moehler M., Ajani J. A., Kuzdzal J., Zander T., Van Cutsem E., Piessen G., Mendez G., Feliciano J., Motoyama S., Lievre A., Uronis H., Elimova E., Grootsholten C., Geboes K., Zhang J., Soleymani S., Lei M., Kondo K., Cleary J., Kelly R. J.

Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer (EC/GEJC) following neoadjuvant chemoradiotherapy (CRT): 14-month follow-up of CheckMate 577
ANNALS OF ONCOLOGY. 2021; 32: S1045-S1046. Meeting Abstract

Moehler M., Elimova E., Blum ?, Xiao H., Davenport E., Wang J., Hunter S., Li M., Kondo K., Wyrwicz L.
Health-related quality of life (HRQOL) in patients (pts) with advanced gastric cancer/gastroesophageal junction cancer (GC/GEJC) or esophageal adenocarcinoma (EAC): Interim results of nivolumab plus chemotherapy (N plus C) versus (C) from CheckMate 649
ONCOLOGY RESEARCH AND TREATMENT. 2021; 44: 214-215. Meeting Abstract

Moehler M., Goyal L., Meric-Bernstam F., Hollebecque A., Morizane C., Valle J. W., Karasic T. B., Abrams T. A., Kelley R. K., Cassier P., Furuse J., Klumpen H. -J, Chang H. -M, Chen L. -T, Komatsu Y., Masuda K., Ahn D., He Y., Soni N., Benhadji K. A., Bridgewater J. A.
Primary results of phase 2 FOENIX-CCA2: the irreversible FGFR1-4 inhibitor futibatinib in intrahepatic cholangiocarcinoma (iCCA) with FGFR2 fusions/rearrangements
ONCOLOGY RESEARCH AND TREATMENT. 2021; 44: 222-222. Meeting Abstract

Moehler M., Shitara K., Garrido M., Salman P., Shen L., Wyrwicz L., Yamaguchi K., Skoczylas T., Bragagnoli Campos A., Liu T., Schenker M., Yanez P., Tehfe M., Li M., Cullen D., Memaj A., Lei M., Xiao H., Janjigian Y. Y., Ajani J. A.
First-line (1L) nivolumab (NIVO) plus chemotherapy (chemo) vs chemo in advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): expanded efficacy and safety data from CheckMate 649
ONCOLOGY RESEARCH AND TREATMENT. 2021; 44: 79-80. Meeting Abstract

Moehler M., Valle J. W., Hollebecque A., Furuse J., Goyal L., Meric-Bernstam F., Epstein R., Salimi T., Wacheck V, Liu M., Benhadji K. A., Bridgewater J. A.
Foenix-CCA2 quality of life data for Futibatinib-treated intrahepatic cholangiocarcinoma (ICCA) patients with FGFR2 fusions/rearrangements
ONCOLOGY RESEARCH AND TREATMENT. 2021; 44: 223-224. Meeting Abstract

Moehler Markus

My Highlights at ASCO 2021: Breakthrough in Immunotherapy for Esophageal and Gastric Cancer
ZEITSCHRIFT FUR GASTROENTEROLOGIE. 2021; 59(11): 1240-1241. Editorial Material

Moehler Markus, Dvorkin Mikhail, Boku Narikazu, Ozguroglu Mustafa, Ryu Min-Hee, Muntean Alina S., Lonardi Sara, Nechaeva Marina, Bragagnoli Arinilda C., Coskun Hasan S., Cubillo Gracian Antonio, Takano Toshimi, Wong Rachel, Safran Howard, Vaccaro Gina M., Wainberg Zev A., Silver Matthew R., Xiong Huiling, Hong Janet, Taieb Julien, Bang Yung-Jue
Phase III Trial of Avelumab Maintenance After First-Line Induction Chemotherapy Versus Continuation of Chemotherapy in Patients With Gastric Cancers: Results From JAVELIN Gastric 100
JOURNAL OF CLINICAL ONCOLOGY. 2021; 39(9). Article

Moehler Markus, Folprecht Gunnar, Heinemann Volker, Holch Julian Walter, Maderer Annett, Kasper Stefan, Hegewisch-Becker Susanna, Schroeder Jan, Overkamp Friedrich, Kullmann Frank, Bechstein Wolf Otto, Voehringer Matthias, Oellinger Robert, Lordick Florian, Geissler Michael, Schulz-Abelius Armin, Linz Bernhard, Bernhard Helga, Paul Andreas, Schmidtman Irene, Potthoff Karin, Schimanski Carl Christoph

Survival after secondary liver resection in metastatic colorectal cancer: Comparing data of three prospective randomized European trials (LICC, CELIM, FIRE-3)
INTERNATIONAL JOURNAL OF CANCER. 2021; 150(8): 1341-1349. Article

Moehler Markus, Michel Maurice, Stein Alexander, Trojan Joerg, Marquardt Jens, Tintelnot Joseph, Waidmann Oliver, Weinmann Arndt, Woerns Marcus-Alexander, Schroeder Helge, Maenz Martin, Foerster Friedrich
A Phase I dose-escalation study of third-line regorafenib with trifluridine/tipiracil in metastatic colorectal cancer
FUTURE ONCOLOGY. 2021; 17(25): 3309-3319. Article

Moehler Markus H., Shitara Kohei, Garrido Marcelo, Salman Pamela, Shen Lin, Wyrwicz Lucjan, Yamaguchi Kensei, Skoczylas Tomasz, Bragagnoli Arinilda Silva Campos, Liu Tianshu, Schenker Michael, Yanez Patricio Eduardo, Tehfe Mustapha, Li Mingshun, Cullen Dana, Memaj Arteid, Lei Ming, Xiao Hong, Janjigian Yelena Y., Ajani Jaffer A.
First-line (1L) nivolumab (NIVO) plus chemotherapy (chemo) versus chemo in advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): Expanded efficacy and safety data from CheckMate 649.
JOURNAL OF CLINICAL ONCOLOGY. 2021; 39(15). Meeting Abstract

Nettelbeck Dirk M., Leber Mathias F., Altomonte Jennifer, Angelova Assia, Beil Julia, Berchtold Susanne, Delic Maike, Eberle Juergen, Ehrhardt Anja, Engeland Christine E., Fechner Henry, Geletneky Karsten, Goepfert Katrin, Holm Per Sonne, Kochanek Stefan, Kreppel Florian, Krutzke Lea, Kuehnel Florian, Lang Karl Sebastian, Marchini Antonio, Moehler Markus, Muehlebach Michael D., Naumann Ulrike, Nawroth Roman, Nueesch Jurg, Rommelaere Jean, Lauer Ulrich M., Ungerechts Guy
Virotherapy in Germany-Recent Activities in Virus Engineering, Preclinical Development, and Clinical Studies
VIRUSES-BASEL. 2021; 13(8). Review

Oh Do-Youn, de Braud Filippo, Bridgewater John, Furuse Junji, Hsu Chih-Hung, Ikeda Masafumi, Lee Sunyoung, Moehler Markus, Park Joon Oh, Shen Lin, Yoo Changhoon, Helwig Christoph, Osada Motonobu, Borad Mitesh
Phase 2/3 study of bintrafusp alfa with gemcitabine plus cisplatin as first-line treatment of biliary tract cancer
ANNALS OF ONCOLOGY. 2021; 32: S333-S333. Meeting Abstract

Pavlakakis N., Shitara K., Sjoquist K., Martin A. J., Jaworski A., Yip S., Oh D-Y., Moehler M., Chen L-T., Bekaii-Saab T., Simes J., Goldstein D.
INTEGRATE IIb: A randomised phase III open label study of regorafenib plus nivolumab vs standard chemotherapy in refractory advanced gastro-oesophageal cancer (AGOC)
ANNALS OF ONCOLOGY. 2021; 32: S1074-S1074. Meeting Abstract

Schwaegermann Marie-Kristin, Schranz Melanie, Moehler Markus, Labenz Christian, Moringlane Alice, Schmidt Marcus, Theobald Matthias, Hess Georg
Any progress in informed consenting for cancer treatment? Results from a cross sectional analysis at a comprehensive cancer center
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY. 2021; 147(7): 2117-2126. Article

Shah Manish A., Bennouna Jaafar, Doi Toshihiko, Shen Lin, Kato Ken, Adenis Antoine, Mamon Harvey J., Moehler Markus, Fu Xiaolong, Cho Byoung Chul, Bordia Sonal, Bhagia Pooja, Shih Chie-Schin, Desai Anjali, Enzinger Peter

KEYNOTE-975 study design: a Phase III study of definitive chemoradiotherapy plus pembrolizumab in patients with esophageal carcinoma

FUTURE ONCOLOGY. 2021; 17(10): 1143-1153. Review

Smyth Elizabeth Catherine, Peeters Ellen, Knoedler Maren Kristina, Giraut Anne, Wagner Anna Dorothea, Moehler Markus H., van Grieken Nicole C. T., Nilsson Magnus, Mauer Murielle E., Lordick Florian

EORTC 1707 VESTIGE: Adjuvant immunotherapy in patients with resected gastric cancer following preoperative chemotherapy with high risk for recurrence (ypN+ and/ or R1)-An open-label randomized controlled phase II study.

JOURNAL OF CLINICAL ONCOLOGY. 2021; 39(15). Meeting Abstract

Stahler Arndt, Heinemann Volker, Holch Julian Walter, von Einem Jobst Christian, Westphalen Christoph Benedikt, Heinrich Kathrin, Schlieker Laura, Jelas Ivan, Alig Annabel Helga Sophie, Fischer Laura Elisabeth, Weiss Lena, Modest Dominik Paul, von Weikersthal Ludwig Fischer, Decker Thomas, Kiani Alexander, Moehler Markus, Kaiser Florian, Kirchner Thomas, Jung Andreas, Stintzing Sebastian
Mutational profiles of metastatic colorectal cancer treated with FOLFIRI plus cetuximab or bevacizumab before and after secondary resection (AIO KRK 0306; FIRE-3)

INTERNATIONAL JOURNAL OF CANCER. 2021; 149(11): 1935-1943. Article

Van Cutsem Eric, Singh Prianka, Cleary James M., Kelly Ronan Joseph, Moehler Markus H., Kuzdzal Jaroslaw, Mendez Guillermo, Motoyama Satoru, Elimova Elena, Grootsholten Cecile, Sun Xiaowu ?, Taylor Fiona, Lawrance Rachael, Padilla Brad, Moreno-Koehler Alejandro, Zhang Jenny, Blum ?, Ajani Jaffer A.

Checkmate 577:Health-related quality of life (HRQoL) in a randomized, double-blind phase III study of nivolumab (NIVO) versus placebo (PBO) as adjuvant treatment in patients (pts) with resected esophageal or gastroesophageal junction cancer (EC/GEJC).

JOURNAL OF CLINICAL ONCOLOGY. 2021; 39(3). Meeting Abstract

Wyrwicz Lucjan, Elimova Elena, Blum Steven I., Xiao Hong, Davenport Eric, Wang Jinyi, Hunter Shannon, Li Mingshun, Kondo Kaoru, Moehler Markus H.

Health-related quality of life (HRQOL) in patients (pts) with advanced gastric cancer/gastroesophageal junction cancer (GC/GEJC) or esophageal adenocarcinoma (EAC): Interim results of nivolumab plus chemotherapy (N plus C) versus (C) from CheckMate 649.

JOURNAL OF CLINICAL ONCOLOGY. 2021; 39(15). Meeting Abstract

Zander T., Kelly R. J., Ajani J. A., Kuzdzal J., van Cutsem E., Piessen G., Mendez G., Feliciano J., Motoyama S., Lievre A., Uronis H., Elimova E., Grootsholten C., Geboes K., Zhang J., Soleymani S., Lei M., Singh P., Cleary J. M., Moehler M.

Adjuvant nivolumab (NIVO) in resected esophageal or gastroesophageal junction cancer (EC/GEJC) following neoadjuvant chemoradiotherapy (CRT): expanded efficacy and safety analyses from CheckMate 577

ONCOLOGY RESEARCH AND TREATMENT. 2021; 44: 80-81. Meeting Abstract

Bergholz Liana M., Grimminger Peter, Dikeoulia Elsa, Rossmann Heidi, Weinmann Arndt, Moehler Markus, Zimmermann Tim, Weber Matthias M., Galle Peter R., Kaina Bernd, Zimmermann Anca

Pilot Study on Malnutrition and DNA Damage in Patients with Newly Diagnosed Gastrointestinal Tumors: Is DNA Damage Reversible by Early Individualized Nutritional Support?
JOURNAL OF GASTROINTESTINAL AND LIVER DISEASES. 2020; 29(4): 569-577. Article

Borad Mitesh J., Bridgewater John A., Morizane Chigusa, Shroff Rachna T., Oh Do-Youn, Moehler Markus H., Furuse Junji, Benhadji Karim A., He Helen, Valle Juan W.
A phase III study of futibatinib (TAS-120) versus gemcitabine-cisplatin (gem-cis) chemotherapy as first-line (1L) treatment for patients (pts) with advanced (adv) cholangiocarcinoma (CCA) harboring fibroblast growth factor receptor 2 (FGFR2) gene rearrangements (FOENIX-CCA3)
JOURNAL OF CLINICAL ONCOLOGY. 2020; 38(4). Meeting Abstract

Catenacci Daniel V. T., Rosales Minori Koshiji, Wigginton Jon M., Chung Hyun Cheol, Yoon Harry H., Shen Lin, Moehler Markus H., Kang Yoon-Koo
Margetuximab (M) combined with anti-PD-1 (MGA012) or anti-PD-1/LAG-3 (MGD013) +/- chemotherapy (CTX) in first-line therapy of advanced/metastatic HER2+gastroesophageal junction (GEJ) or gastric cancer (GC)
JOURNAL OF CLINICAL ONCOLOGY. 2020; 38(4). Meeting Abstract

Chibaudel Benoist, Henriques Julie, Rakez Manel, Brenner Baruch, Kim Tae Won, Martinez-Villacampa Mercedes, Gallego-Plazas Javier, Cervantes Andres, Shim Katharine, Jonker Derek, Guerin-Meyer Veronique, Mineur Laurent, Banzi Chiara, Dewdney Alice, Dejthevaporn Thitiya, Bloemendal Haiko J., Roth Arnaud, Moehler Markus, Aranda Enrique, Van Cutsem Eric, Tabertero Josep, Schmoll Hans-Joachim, Hoff Paulo M., Andre Thierry, de Gramont Aimery
Association of Bevacizumab Plus Oxaliplatin-Based Chemotherapy With Disease-Free Survival and Overall Survival in Patients With Stage II Colon Cancer A Secondary Analysis of the AVANT Trial
JAMA NETWORK OPEN. 2020; 3(10). Article

Fontana Elisa, Zichi Clizia, Smyth Elizabeth Catherine, Mauer Murielle E., Roedel Claus, Fokas Emmanouil, Hofheinz Ralf Dieter, Arnold Dirk, Schmoll Hans-Joachim, Van Cutsem Eric, Haustermans Karin, Stein Alexander, Gerard Jean-Pierre, Conroy Thierry, Jouffroy-Zeller Claire, Moehler Markus H., Lordick Florian, Ben-Aharon Irit, Di Maio Massimo
Neoadjuvant chemoradiation (CRT) for locally advanced rectal cancer (LARC) with or without oxaliplatin (OX): Individual patient data (IPD) meta-analysis of three randomized controlled trials (RCTs) with subgroup analyses of age cohorts.
JOURNAL OF CLINICAL ONCOLOGY. 2020; 38(15). Meeting Abstract

Hacker Ulrich T., Hasenclever Dirk, Linder Nicolas, Stocker Gertraud, Chung Hyun-Cheol, Kang Yoon-Koo, Moehler Markus, Busse Harald, Lordick Florian
Prognostic role of body composition parameters in gastric/gastroesophageal junction cancer patients from the EXPAND trial
JOURNAL OF CACHEXIA SARCOPENIA AND MUSCLE. 2020; 11(1): 135-144. Article

Levy Antonin, Wagner Anna D., Chargari Cyrus, Moehler Markus, Verheij Marcel, Durand-Labrunie Jerome, Kissel Manon, Chirat Erick, Burtin Pascal, Ducreux Michel, Boige Valerie, Nilsson Magnus, Boku Narikazu, Chau Ian, Deutsch Eric
Palliation of dysphagia in metastatic oesogastric cancers: An international multidisciplinary position
EUROPEAN JOURNAL OF CANCER. 2020; 135: 103-112. Review

McNamara Mairead Geraldine, Lopes Andre, Wasan Harpreet, Malka David, Goldstein David, Shannon Jenny, Okusaka Takuji, Knox Jennifer J., Wagner Anna Dorothea, Andre Thierry, Cunningham David, Moehler Markus, Jensen Lars Henrik, Koeberle Dieter, Bekaii-Saab Tanios, Bridgewater John, Valle Juan W.

Landmark survival analysis and impact of anatomic site of origin in prospective clinical trials of biliary tract cancer

JOURNAL OF HEPATOLOGY. 2020; 73(5): 1109-1117. Article

Moehler M., Maderer A., Thuss-Patience P. C., Brenner B., Meiler J., Ettrich T. J., Hofheinz R-D, Al-Batran S. E., Vogel A., Mueller L., Lutz M. P., Lordick F., Alsina M., Borchert K., Greil R., Eisterer W., Schad A., Slotta-Huspenina J., Van Cutsem E., Lorenzen S.

Cisplatin and 5-fluorouracil with or without epidermal growth factor receptor inhibition panitumumab for patients with non-resectable, advanced or metastatic oesophageal squamous cell cancer: a prospective, open-label, randomised phase III AIO/EORTC trial (POWER)

ANNALS OF ONCOLOGY. 2020; 31(2): 228-235. Article

Moehler M., Stein A., Trojan J., Marquardt J., Quidde J., Waidmann O., Weinmann A., Woerns M., Schroeder H., Maenz M., Karatas A.

Regorafenib with TAS-102 in metastatic colorectal cancer patients who progressed after at least two standard therapies: Efficacy and safety results of a multicenter phase I study (REMETY)

ANNALS OF ONCOLOGY. 2020; 31: S214-S214. Meeting Abstract

Moehler Markus H., Dvorkin Mikhail, Ozguroglu Mustafa, Ryu Min-hee, Muntean Alina Simona, Lonardi Sara, Nechaeva Marina, Bragagnoli Arinilda Silva Campos, Coskun Hasan Senol, Gracian Antonio Cubillo, Takano Toshimi, Wong Rachel, Safran Howard, Vaccaro Gina M., Boku Narikazu, Conti Iliaria, Hong Janet, Xiong Huiling, Taieb Julien, Bang Yung-Jue

Results of the JAVELIN Gastric 100 phase 3 trial: avelumab maintenance following first-line (1L) chemotherapy (CTx) vs continuation of CTx for HER2-advanced gastric or gastroesophageal junction cancer (GC/GEJC)

JOURNAL OF CLINICAL ONCOLOGY. 2020; 38(4). Meeting Abstract

Moehler Markus H., Stein Alexander, Trojan Jorg, Marquardt Jens Uwe, Quidde Julia, Waidmann Oliver, Weinmann Arndt, Woerns Marcus, Schroeder Helge, Maenz Martin, Karatas Aysun, Foerster Friedrich

Regorafenib with TAS-102 (REGOTAS) in metastatic colorectal cancer patients who progressed after at least two standard therapies: Efficacy and safety results of a multicenter phase I study (REMETY)

JOURNAL OF CLINICAL ONCOLOGY. 2020; 38(4). Meeting Abstract

Monig Stefan, Ott Katja, Gockel Ines, Lorenz Dietmar, Ludwig Kaja, Messmann Helmut, Moehler Markus, Piso Pompiliu, Weimann Arved, Meyer Hans-Joachim

S3 guidelines on gastric cancer-diagnosis and treatment of adenocarcinoma of the stomach and esophagogastric junction Version 2.0-August 2019. AWMF register number: 032/009OL

CHIRURG. 2020; 91(1): 37-40. Article

Moore Assaf, Hikri Elad, Goshen-Lago Tal, Barkan Tamar, Morgenstern Sara, Brook Elena, Maderer Annett, Roth Wilfried, Gordon Noa, Kashtan Hanoach, Brenner Baruch, Moehler Markus, Aharon Irit Ben

Young-onset gastric cancer and Epstein-Barr Virus (EBV) - a major player in the pathogenesis?

BMC CANCER. 2020; 20(1). Article

Oba Koji, Paoletto Xavier, Bang Yung-Jue, Bouche Olivier, Ducreux Michel, Michiels Stefan, Moehler Markus, Morita Satoshi, Ohashi Yasuo, Sakamoto Junichi, Sasako Mitsuru, Shitara Kohei, Van Cutsem Eric, Buyse Marc E., Burzykowski Tomasz
Progression-free survival (PFS) as a surrogate endpoint for overall survival (OS) in advanced/recurrent gastric cancer (AGC) treatment: Individual-patient-data (IPD) based meta-analysis of randomized trials.
JOURNAL OF CLINICAL ONCOLOGY. 2020; 38(15). Meeting Abstract

Rades Dirk, Bartscht Tobias, Hunold Peter, Schmidberger Heinz, Koenig Laila, Debus Jurgen, Belka Claus, Homann Nils, Spillner Patrick, Petersen Cordula, Kuhnt Thomas, Fietkau Rainer, Ridwelski Karsten, Karcher-Kilian Kerstin, Kranich Anne, Maennikoe Sofia, Schild Steven E., Maderer Annett, Moehler Markus
Radiochemotherapy with or without cetuximab for unresectable esophageal cancer: final results of a randomized phase 2 trial (LEOPARD-2)
STRAHLENTHERAPIE UND ONKOLOGIE. 2020; 196(9): 795-804. Article

Schimanski Carl Christoph, Kasper Stefan, Hegewisch-Becker Susanna, Schroeder Jan, Overkamp Friedrich, Kullmann Frank, Bechstein Wolf Otto, Voehringer Matthias, Oellinger Robert, Lordick Florian, Heinemann Volker, Geissler Michael, Schulz-Abelius Armin, Bernhard Helga, Schoen Michael R., Greil Richard, Galle Peter, Lang Hauke, Schmidtmann Irene, Moehler Markus
Adjuvant MUC vaccination with tecemotide after resection of colorectal liver metastases: a randomized, double-blind, placebo-controlled, multicenter AIO phase II trial (LICC)
ONCOIMMUNOLOGY. 2020; 9(1). Article

Schulz Christoph, Heinemann Volker, Heinrich Kathrin, Haas Michael, Holch Julian W., Fraccaroli Alessia, Held Swantje, von Einem Jobst C., Modest Dominik P., von Weikersthal Ludwig Fischer, Kullmann Frank, Moehler Markus, Scheithauer Werner, Jung Andreas, Stintzing Sebastian
Predictive and prognostic value of magnesium serum level in FOLFIRI plus cetuximab or bevacizumab treated patients with stage IV colorectal cancer: results from the FIRE-3 (AIO KRK-0306) study
ANTI-CANCER DRUGS. 2020; 31(8): 856-865. Article

Smyth Elizabeth, Knoedler Maren, Giraut Anne, Mauer Murielle, Nilsson Magnus, Van Grieken Nicole, Wagner Anna Dorothea, Moehler Markus, Lordick Florian
VESTIGE: Adjuvant Immunotherapy in Patients With Resected Esophageal, Gastroesophageal Junction and Gastric Cancer Following Preoperative Chemotherapy With High Risk for Recurrence (N+ and/or R1): An Open Label Randomized Controlled Phase-2-Study
FRONTIERS IN ONCOLOGY. 2020; 9. Article

Smyth Elizabeth C., Moehler Markus
Pembrolizumab in First-line Gastric Cancer: Win, Lose, or Draw?
JAMA ONCOLOGY. 2020; 6(10): 1539-1541. Editorial Material

Smyth Elizabeth Catherine, Knoedler Maren Kristina, Nilsson Magnus, Wagner Anna Dorothea, Moehler Markus H., van Grieken Nicole C. T., Giraut Anne, Mauer Murielle E., Lordick Florian
EORTC 1707 VESTIGE: Adjuvant immunotherapy in patients with resected gastric cancer following preoperative chemotherapy with high risk for recurrence (ypN+ and/or R1): An open-label randomized controlled phase II study
JOURNAL OF CLINICAL ONCOLOGY. 2020; 38(4). Meeting Abstract

Stahler Arndt, Stintzing Sebastian, Modest Dominik P., Ricard Ingrid, Giessen-Jung Clemens, Kapaun Christine, Ivanova Boryana, Kaiser Florian, von Weikersthal Ludwig Fischer, Moosmann Nicolas, Schalhorn Andreas, Stauch Martina, Kiani Alexander, Held Swantje, Decker Thomas, Moehler Markus, Neumann Jens, Kirchner Thomas, Jung Andreas, Heinemann Volker
Amphiregulin Expression Is a Predictive Biomarker for EGFR Inhibition in Metastatic Colorectal Cancer: Combined Analysis of Three Randomized Trials
CLINICAL CANCER RESEARCH. 2020; 26(24): 6559-6567. Article

Stahler Arndt, Stintzing Sebastian, von Einem Jobst C., Westphalen (Benedikt) Christoph B., Heinrich Kathrin, Kraemer Nicole, Michl Marlies, Modest Dominik P., von Weikersthal Ludwig Fischer, Decker Thomas, Kiani Alexander, Heintges Tobias, Kahl Christoph, Kullmann Frank, Scheithauer Werner, Moehler Markus, Kaiser Florian, Kirchner Thomas, Jung Andreas, Heinemann Volker
Single-nucleotide variants, tumour mutational burden and microsatellite instability in patients with metastatic colorectal cancer: Next-generation sequencing results of the FIRE-3 trial
EUROPEAN JOURNAL OF CANCER. 2020; 137: 250-259. Article

Stahler Arndt, Stintzing Sebastian, von Einem Jobst C., Westphalen C. Benedikt, Kraemer Nicole, Michl Marlies, Modest Dominik Paul, von Weikersthal Ludwig Fischer, Decker Thomas, Kiani Alexander, Heintges Tobias, Kahl Christoph, Kullmann Frank, Scheithauer Werner, Moehler Markus, Vehling-Kaiser Ursula, Kirchner Thomas, Jung Andreas, Heinemann Volker
Somatic Alterations and Tumor Mutational Burden (TMB) in Patients with Metastatic Colorectal Cancer (mCRC) Treated with FOLFIRI Plus Bevacizumab or Cetuximab (Fire-3 Trial)
ONCOLOGY RESEARCH AND TREATMENT. 2020; 43: 48-48. Meeting Abstract

Thomaidis Thomas, Kallimanis George, May Gary, Zhou Pinghong, Sivanathan Visvakanth, Mosko Jeff, Triantafyllidis John K., Teshima Christopher, Moehler Markus
Advances in the endoscopic management of malignant biliary obstruction
ANNALS OF GASTROENTEROLOGY. 2020; 33(4): 338-+. Review

Wagner Anna D., Lordick Florian, Grabsch ?, Terashima Masanori, Terada Mitsumi, Yoshikawa Takaki, Boku Narikazu, Kataoka Kozo, Smyth Elizabeth C., Mauer Murielle, Haustermans Karin, Moehler Markus H.
Multidisciplinary management of stage II-III gastric and gastro-oesophageal junction cancer
EUROPEAN JOURNAL OF CANCER. 2020; 124: 67-76. Review

Woermann Bernhard, Bokemeyer Carsten, Burmeister Thomas, Koehne Claus-Henning, Schwab Matthias, Arnold Dirk, Blohmer Jens-Uwe, Borner Markus, Brucker Sara, Cascorbi Ingolf, Decker Thomas, de Wit Maïke, Dietz Andreas, Einsele Hermann, Eisterer Wolfgang, Folprecht Gunnar, Hilbe Wolfgang, Hoffmann Jurgen, Knauf Wolfgang, Kunzmann Volker, Largiader Carlo R., Lorenzen Sylvie, Luftner Diana, Moehler Markus, Nothen Markus M., Pox Christian, Reinacher-Schick Anke, Scharl Anton, Schlegelberger Brigitte, Seufferlein Thomas, Sinn Marianne, Stroth Matthias, Tamm Ingo, Trumper Lorenz, Wilhelm Martin, Woell Ewald, Hofheinz Ralf-Dieter
Dihydropyrimidine Dehydrogenase Testing prior to Treatment with 5-Fluorouracil, Capecitabine, and Tegafur: A Consensus Paper
ONCOLOGY RESEARCH AND TREATMENT. 2020; 43(11): 628-636. Review

Xu Rui-hua, Arkenau Hendrik-Tobias, Bang Yung-Jue, Denlinger Crystal S., Kato Ken, Tabernero Josep, Wang Jin, Li Jiang, Castro Henry, Moehler Markus H.

Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line therapy in patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma

JOURNAL OF CLINICAL ONCOLOGY. 2020; 38(4). Meeting Abstract

Zander Thomas, Moehler Markus

Multimodal therapy of gastric cancer

ONKOLOGE. 2020; 26(10): 912-917. Article

Al-Batran Salah-Eddin, Homann Nils, Pauligk Claudia, Goetze Thorsten O., Meiler Johannes, Kasper Stefan, Kopp Hans-Georg, Mayer Frank, Haag Georg Martin, Luley Kim, Lindig Udo, Schmiegel Wolff, Pohl Michael, Stoehlmacher Jan, Folprecht Gunnar, Probst Stephan, Prasnikar Nicole, Fischbach Wolfgang, Mahlberg Rolf, Trojan Joerg, Koenigsmann Michael, Martens Uwe M., Thuss-Patience Peter, Egger Matthias, Block Andreas, Heinemann Volker, Illerhaus Gerald, Moehler Markus, Schenk Michael, Kullmann Frank, Behringer Dirk M., Heike Michael, Pink Daniel, Teschendorf Christian, Loehr Carmen, Bernhard Helga, Schuch Gunter, Rethwisch Volker, von Weikersthal Ludwig Fischer, Hartmann Joerg T., Kneba Michael, Daum Severin, Schulmann Karsten, Weniger Joerg, Belle Sebastian, Gaiser Timo, Oduncu Fuat S., Guentner Martina, Hozaeel Wael, Reichart Alexander, Jaeger Elke, Kraus Thomas, Moenig Stefan, Bechstein Wolf O., Schuler Martin, Schmalenberg Harald, Hofheinz Ralf D.

Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial

LANCET. 2019; 393(10184): 1948-1957. Article

Catenacci Daniel, Rosales Minori, Wigginton Jon, Chung Hyun Cheol, Yoon Harry, Shen Lin, Kang Yoon-Koo, Moehler Markus

Margetuximab combined with anti-PD-1 (MGA012) or anti-PD-1/LAG-3 (MGD013) +/- chemotherapy in first-line therapy of advanced/metastatic HER2+gastroesophageal junction (GEJ) or gastric cancer (GC)

JOURNAL FOR IMMUNOTHERAPY OF CANCER. 2019; 7. Meeting Abstract

De Gramont A., Henriques J., Baruch B., Kim T. W., Martinez-Villacampa M., Gallego-Plazas J., Cervantes A., Shim K., Jonker D. J., Guerin-Meyer V., Mineur L., Banzi M., Dewdney A., Dejthevaporn T., Sirisingha, Bloemendal H. J., Roth A. D., Thompson P., Moehler M., Aranda Aguilar E., Andre T. Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (CC): Updated analysis of stage II disease from the AVANT phase III randomized trial by the GERCOR group ANNALS OF ONCOLOGY. 2019; 30. Meeting Abstract

Desuki Alexander, Staib Frank, Gockel Ines, Moehler Markus, Lang Hauke, Biesterfeld Stefan, Maderer Annett, Galle Peter R., Berger Martin R., Schimanski Carl C.

Loss of LLGL1 Expression Correlates with Diffuse Gastric Cancer and Distant Peritoneal Metastases CANADIAN JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY. 2019. Article

Goepfert Katrin, Dinsart Christiane, Rommelaere Jean, Foerster Friedrich, Moehler Markus Rational Combination of Parvovirus H1 With CTLA-4 and PD-1 Checkpoint Inhibitors Dampens the Tumor Induced Immune Silencing

FRONTIERS IN ONCOLOGY. 2019; 9. Article

Goyal Lipika, Bahleda Rastilav, Furuse Junji, Valle Juan W., Moehler Markus Hermann, Oh Do-Youn, Chang Heung-Moon, Kelley Robin Kate, Javle Milind M., Borad Mitesh J., Chen Li-Tzong, Uboha Nataliya Volodymyrivna, Klumpen Heinz-Josef, O'Dwyer Peter J., Li Daneng, Morizane Chigusa, Huang Jerry, Bridgewater John A.

FOENIX-101: A phase II trial of TAS-120 in patients with intrahepatic cholangiocarcinoma harboring FGFR2 gene rearrangements.

JOURNAL OF CLINICAL ONCOLOGY. 2019; 37(4). Meeting Abstract

Grivas Petros, Monk Bradley J., Petrylak Daniel, Reck Martin, Foley Grace, Guenther Silke, Hennessy Dan, Makris Constantin, Moehler Markus

Immune Checkpoint Inhibitors as Switch or Continuation Maintenance Therapy in Solid Tumors: Rationale and Current State

TARGETED ONCOLOGY. 2019; 14(5): 505-525. Review

Heinrich Stefan, Besselink Marc, Moehler Markus, van Laethem Jean-Luc, Ducreux Michel, Grimminger Peter, Mittler Jens, Lang Hauke, Lutz Manfred P., Lesurtel Mickael

Opinions and use of neoadjuvant therapy for resectable, borderline resectable, and locally advanced pancreatic cancer: international survey and case-vignette study

BMC CANCER. 2019; 19. Article

Holch J. W., Ricard I., Stintzing S., von Weikersthal L. Fischer, Decker T., Kiani A., Vehling-Kaiser U., Heintges T., Kahl C., Kullmann F., Scheithauer W., Moehler M., Jelas I., Modest D. P., Westphalen C. B., von Einem J. C., Michl M., Heinemann V.

Relevance of baseline carcinoembryonic antigen for first-line treatment against metastatic colorectal cancer with FOLFIRI plus cetuximab or bevacizumab (FIRE-3 trial)

EUROPEAN JOURNAL OF CANCER. 2019; 106: 115-125. Article

Lang Hauke, Baumgart Janine, Heinrich Stefan, Tripke Verena, Passalacqua Monia, Maderer Annett, Galle Peter R., Roth Wilfried, Kloth Michael, Moehler Markus

Extended Molecular Profiling Improves Stratification and Prediction of Survival After Resection of Colorectal Liver Metastases

ANNALS OF SURGERY. 2019; 270(5): 799-805. Article

Lutz Manfred P., Zalcborg John R., Ducreux Michel, Adenis Antoine, Allum William, Aust Daniela, Carneiro Fatima, Grabsch ?, Laurent-Puig Pierre, Lordick Florian, Moehler Markus, Monig Stefan, Obermannova Radka, Piessen Guillaume, Riddell Angela, Roecken Christoph, Roviello Franco, Schneider Paul Magnus, Seewald Stefan, Smyth Elizabeth, van Cutsem Eric, Verheij Marcel, Wagner Anna Dorothea, Otto Florian

The 4th St. Gallen EORTC Gastrointestinal Cancer Conference: Controversial issues in the multimodal primary treatment of gastric, junctional and oesophageal adenocarcinoma

EUROPEAN JOURNAL OF CANCER. 2019; 112: 1-8. Review

McNamara M. G., Lopes A., Wasan H., Malka D., Goldstein D., Shannon J., Okusaka T., Knox J. J., Wagner A. D., Andre T., Cunningham D., Moehler M., Jensen L. H., Koeberle D., Bekaii-Saab T., Bridgewater J. A., Valle J. W.

Impact of anatomic site of biliary tract tumour origin and conditional probability of survival (CS): Results from 15 prospective advanced first-line clinical trial

ANNALS OF ONCOLOGY. 2019; 30: 274-274. Meeting Abstract

Miller-Phillips Lisa, Heinemann Volker, Stahler Arndt, von Weikersthal Ludwig Fischer, Kaiser Florian, Al-Batran Salah-Eddin, Neureiter Daniel, Kahl Christoph, Kullmann Frank, Moehler Markus H., Scheithauer Werner, Vazart Celine, Fontaine Karine, Held Swantje, Modest Dominik Paul, Neumann Jens, Jung Andreas, Kirchner Thomas, Stintzing Sebastian
Association of microRNA-21 with efficacy of cetuximab in RAS wild-type patients in the FIRE-3 study (AIO KRK-0306) and microRNA-21's influence on gene expression in the EGFR signaling pathway.
JOURNAL OF CLINICAL ONCOLOGY. 2019; 37(15). Meeting Abstract

Moehler Markus

Updated S3 Guideline for Gastric Cancer now published

ZEITSCHRIFT FUR GASTROENTEROLOGIE. 2019; 57(12): 1515-1516. Editorial Material

Moehler Markus, Al-Batran Salah-Edin, Andus Tilo, Arends Jann, Arnold Dirk, Baretton Gustavo, Bornschein Jan, Budach Wilfried, Daum Severin, Dietrich Christoph, Ebert Matthias, Fischbach Wolfgang, Flentje Michael, Gockel Ines, Grenacher Lars, Haier Joerg, Hoecht Stefan, Jakobs Rolf, Jenssen Christian, Kade Barbara, Kanzler Stefan, Langhorst Jost, Link Hartmut, Lordick Florian, Lorenz Dietmar, Lorenzen Sylvie, Lutz Manfred, Messmann Helmut, Meyer Hans-Joachim, Moenig Stefan, Ott Katja, Quante Michael, Roecken Christoph, Schlattmann Peter, Schmiegel Wolff-H., Schreyer Andreas, Tannapfel Andrea, Thuss-Patience Peter, Weimann Arved, Unverzagt Susanne
S3 Guideline Gastric Carcinoma - Diagnosis and Therapy of Gastric Adenocarcinomas and the esophagogastral Transition - Long Version 2.0-August 2019. AWMF Registration Number: 032 / 009OL

ZEITSCHRIFT FUR GASTROENTEROLOGIE. 2019; 57(12): 1517-1632. Article

Moehler Markus, Langer Thomas, Bender Tanja, Kofent Julia, Greiwe Friederike, Jost Heinrike, Koukli Georgia, Orthey Annika, Rolfes Carolin, Wald Catharina, Wesselmann Simone, Follmann Markus, Unverzagt Susanne

Guideline Report on the S3 Guideline Gastric Carcinoma - "Diagnostics and Therapy of Gastric Adenocarcinomas and esophagogastral Transition" Version 2.0-August 2019-AWMF Register Number: 032/009OL

ZEITSCHRIFT FUR GASTROENTEROLOGIE. 2019; 57(12): E418-E671. Article

Moehler Markus, Maderer Annett, Ehrlich Anne, Foerster Friedrich, Schad Arno, Nickolay Tanja, Ruckes Christian, Weinmann Arndt, Sivanathan Visvakanth, Marquardt Jens U., Galle Peter Robert, Woerns Marcus, Thomaidis Thomas

Safety and efficacy of afatinib as add-on to standard therapy of gemcitabine/cisplatin in chemotherapy-naive patients with advanced biliary tract cancer: an open-label, phase I trial with an extensive biomarker program

BMC CANCER. 2019; 19. Article

Moehler Markus, Ryu Min-Hee, Dvorkin Mikhail, Lee Keun-Wook, Coskun Hasan S., Wong Rachel, Chung Hyun C., Poltoratsky Artem, Tsuji Akihito, Yen Chia Jui, Muntean Alina S., Le Sourd Samuel, Vaccaro Gina M., Overton Lindsay, Boku Narikazu, Wainberg Zev A., Patel Manish, Sharma Maitreyi, Xiong Huiling, Conti Ilaria, Taieb Julien, Bang Yung-Jue

Maintenance avelumab versus continuation of first-line chemotherapy in gastric cancer: JAVELIN Gastric 100 study design

FUTURE ONCOLOGY. 2019; 15(6): 567-577. Article

Moehler Markus Hermann, Folprecht Gunnar, Heinemann Volker, Holch Julian, Maderer Annett, Kasper Stefan, Hegewisch-Becker Susanna, Schroeder Jan, Overkamp Friedrich, Kullmann Frank, Bechstein Wolf Otto, Voehringer Matthias, Oellinger Robert, Lordick Florian, Geissler Michael, Schulz-Abelius Armin, Linz Bernhard, Bernhard Helga, Schmidtmann Irene, Schimanski Carl Christoph
Survival after secondary liver resection in metastatic colorectal cancer: A comparative analysis of the LICC trial with historical controls (CELIM, FIRE-3).

JOURNAL OF CLINICAL ONCOLOGY. 2019; 37(15). Meeting Abstract

Moehler Markus Hermann, Folprecht Gunnar, Heinemann Volker, Holch Julian, Maderer Annett, Kasper Stefan, Hegewisch-Becker Susanna, Schroeder Jan, Overkamp Friedrich, Kullmann Frank, Bechstein Wolf Otto, Voehringer Matthias, Oellinger Robert, Lordick Florian, Geissler Michael, Schulz-Abelius Armin, Linz Bernhard, Bernhard Helga, Schmidtmann Irene, Schimanski Carl Christoph
Survival after secondary liver resection in metastatic colorectal cancer: A comparative analysis of the LICC trial with historical controls (CELIM, FIRE-3).

JOURNAL OF CLINICAL ONCOLOGY. 2019; 37(4). Meeting Abstract

Schimanski Carl Christoph, Kasper Stefan, Hegewisch-Becker Susanna, Schroeder Jan, Overkamp Friedrich, Kullmann Frank, Bechstein Wolf Otto, Voehringer Matthias, Oellinger Robert, Lordick Florian, Heinemann Volker, Geissler Michael, Schulz-Abelius Armin, Linz Bernhard, Bernhard Helga, Potthoff Karin, Schmidtmann Irene, Moehler Markus Hermann

Survival after primary liver resection in metastatic colorectal cancer: A comparative analysis of the LICC trial with historical controls (FFCD ACHBTH AURC 9002 trial and EORTC Intergroup trial 40983).

JOURNAL OF CLINICAL ONCOLOGY. 2019; 37(15). Meeting Abstract

Schimanski Carl Christoph, Kasper Stefan, Hegewisch-Becker Susanna, Schroeder Jan, Overkamp Friedrich, Kullmann Frank, Bechstein Wolf Otto, Vohringer Matthias, Oellinger Robert, Lordick Florian, Heinemann Volker, Geissler Michael, Schulz-Abelius Armin, Linz Bernhard, Bernhard Helga, Schoen Michael R., Greil Richard, Smith-Machnow Victoria, Schmidtmann Irene, Moehler Markus Hermann

A randomized, double-blinded, placebo-controlled multicenter phase II trial of adjuvant immunotherapy with tecemotide (L-BLP25) after R0/R1 hepatic colorectal cancer metastasectomy (LICC): Final results.

JOURNAL OF CLINICAL ONCOLOGY. 2019; 37(4). Meeting Abstract

Sivanathan Visvakanth, Thomaidis Thomas, Stahl Michael, Utz Christoph, Maderer Annett, Lordick Florian, Mihaljevic Andre, Kanzler Stephan, Hohler Thomas, Thuss-Patience Peter, Moenig Stefan, Kunzmann Volker, Schroll Sebastian, Ibach Stefan, Tannapfel Andrea, Meyer Hans-Joachim, Schuhmacher Christoph, Wilke Hans Jochen, Krause Katrin, Karatas Aysun, Galle Peter R., Moehler Markus

PREDICTIVE SIGNIFICANCE OF ENDOSONOGRAPHIC (EUS) STAGING IN LOCALLY ADVANCED GASTRIC (GC) OR GASTROESOPHAGEAL-JUNCTION (AEG) ADENOCARCINOMA: ANALYSIS OF DATA FROM A PERIOPERATIVE AIO-CAO PHASE II STUDY

GASTROENTEROLOGY. 2019; 156(6): S512-S513. Meeting Abstract

Smyth Elizabeth C., Moehler Markus

Late-line treatment in metastatic gastric cancer: today and tomorrow

THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY. 2019; 11. Review

Stahler Arndt, Stintzing Sebastian, Modest Dominik Paul, Jelas Ivan, Heinrich Kathrin, Miller-Phillips Lisa, von Einem Jobst C., Vehling-Kaiser Ursula, Decker Thomas, Kiani Alexander, von Weikersthal Ludwig Fischer, Heintges Tobias, Kahl Christoph, Kullmann Frank, Scheithauer Werner, Moehler Markus H., Wirapati Pratyaksha, Kirchner Thomas, Jung Andreas, Heinemann Volker
Association of MAPK signaling subtypes with prognostic benefit for bevacizumab in left-sided metastatic colorectal cancer (mCRC) patients treated with FOLFIRI plus cetuximab / bevacizumab (FIRE-3 trial).

JOURNAL OF CLINICAL ONCOLOGY. 2019; 37(15). Meeting Abstract

Stintzing S., Wirapati P., Lenz H. J., Neureiter D., von Weikersthal L. Fischer, Decker T., Kiani A., Kaiser F., Al-Batran S., Heintges T., Lerchenmueller C., Kahl C., Seipelt G., Kullmann F., Moehler M., Scheithauer W., Held S., Modest D. P., Jung A., Kirchner T., Aderka D., Tejpar S., Heinemann V
Consensus molecular subgroups (CMS) of colorectal cancer (CRC) and first-line efficacy of FOLFIRI plus cetuximab or bevacizumab in the FIRE3 (AIO KRK-0306) trial

ANNALS OF ONCOLOGY. 2019; 30(11): 1796-1803. Article

Tannapfel Andrea, Reinacher-Schick Anke, Hacker Ulrich, Lorenzen Sylvie, Moehler Markus, Vogel Arndt

Immunotherapy: New Options in Gastrointestinal Cancers?

VISCERAL MEDICINE. 2019; 35(1): 47-51. Editorial Material

Thomaidis Thomas, Maderer Annett, Schad Arno, Ruckes Christian, Weinmann Arndt, Sivanathan Visvakanth, Marquardt Jens U., Foerster Friedrich, Galle Peter R., Woerns Marcus, Moehler Markus
AFATINIB COMBINED WITH GEMCITABINE/CISPLATIN IN CHEMOTHERAPY NAIVE PATIENTS WITH ADVANCED BILIARY TRACT CANCER: RESULTS AND TRANSLATIONAL ANALYSIS OF AN OPEN-LABEL, PHASE I TRIAL

GASTROENTEROLOGY. 2019; 156(6): S1047-S1047. Meeting Abstract

Wagner A. D., Oertelt-Prigione S., Adjei A., Buclin T., Cristina V., Csajka C., Coukos G., Dafni U., Dotto G. -P., Ducreux M., Fellay J., Haanen J., Hocquet A., Klinge I., Lemmens V., Letsch A., Mauer M., Moehler M., Peters S., Ozdemir B. C.

Gender medicine and oncology: report and consensus of an ESMO workshop

ANNALS OF ONCOLOGY. 2019; 30(12): 1914-1924. Review

Wagner Anna Dorothea, Grabsch ?, Mauer Murielle, Marreaud Sandrine, Caballero Carmela, Thuss-Patience Peter, Mueller Lothar, Elme Annelie, Moehler Markus Hermann, Martens Uwe, Kang Yoon-Koo, Rha Sun Young, Cats Annemieke, Tokunaga Masanori, Lordick Florian

EORTC-1203-GITCG - the "INNOVATION"-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction adenocarcinoma on pathologic response rate: a randomized phase II-intergroup trial of the EORTC-Gastrointestinal Tract Cancer Group, Korean Cancer Study Group and Dutch Upper GI-Cancer group

BMC CANCER. 2019; 19. Article

Weise Friederike, Vieth Michael, Reinhold Dirk, Haybaeck Johannes, Goni Elisabetta, Lippert Hans, Ridwelski Karsten, Lingohr Philipp, Schildberg Claus, Vassos Nikolaos, Kruschewski Martin, Krasniuk Iurii, Grimminger Peter P., Waidmann Oliver, Peitz Ulrich, Veits Lothar, Kreuser Nicole, Lang Hauke, Bruns Christiane, Moehler Markus, Lordick Florian, Gockel Ines, Schumacher Johannes, Malferttheiner Peter, Venerito Marino

Gastric cancer in autoimmune gastritis: A case-control study from the German centers of the staR project on gastric cancer research

UNITED EUROPEAN GASTROENTEROLOGY JOURNAL. 2019. Article; Early Access

Xu Rui-hua, Arkenau Hendrik-Tobias, Bang Yung-Jue, Denlinger Crystal S., Kato Ken, Tabertero Josep, Wang Jin, Li Jiang, Castro Henry, Moehler Markus Hermann

A phase III trial-in-progress comparing tislelizumab plus chemotherapy with placebo plus chemotherapy as first-line therapy in patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma.

JOURNAL OF CLINICAL ONCOLOGY. 2019; 37(15). Meeting Abstract

Alsina Maria, Moehler Markus, Lorenzen Sylvie

Immunotherapy of Esophageal Cancer: Current Status, Many Trials and Innovative Strategies

ONCOLOGY RESEARCH AND TREATMENT. 2018; 41(5): 266-271. Review

Bang Y. -J., Ruiz E. Yanez, Van Cutsem E., Lee K. -W., Wyrwicz L., Schenker M., Alsina M., Ryu M. -H., Chung H. -C., Evesque L., Al-Batran S. -E., Park S. H., Lichinitser M., Boku N., Moehler M. H., Hong J., Xiong H., Hallwachs R., Conti I., Taieb J.

Phase III, randomised trial of avelumab versus physician's choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300

ANNALS OF ONCOLOGY. 2018; 29(10): 2052-2060. Article

Doersam Bastian, Seiwert Nina, Foersch Sebastian, Stroh Svenja, Nagel Georg, Begaliew Diana, Diehl Erika, Kraus Alexander, McKeague Maureen, Minneker Vera, Roukos Vassilis, Reissig Sonja, Waisman Ari, Moehler Markus, Stier Anna, Mangerich Aswin, Dantzer Françoise, Kaina Bernd, Fahrner Joerg
PARP-1 protects against colorectal tumor induction, but promotes inflammation-driven colorectal tumor progression

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. 2018; 115(17): E4061-E4070. Article

Ettrich Thomas J., Ebert Matthias, Lorenzen Sylvie, Moehler Markus, Vogel Arndt, Witkowski Lukas, Seufferlein Thomas, Reinacher-Schick Anke

ASCO- and ESMO-update 2017-highlights of the 53. meeting of the American Society of Clinical Oncology/ASCO 2017 and European Society for Medical Oncology/ESMO congress 2017

ZEITSCHRIFT FUR GASTROENTEROLOGIE. 2018; 56(4): 384-397. Article

Heinrichs Sophie K. M., Hess Timo, Becker Jessica, Hamann Lutz, Vashist Yogesh K., Butterbach Katja, Schmidt Thomas, Alakus Hakan, Krasniuk Iurii, Hoeblinger Aksana, Lingohr Philipp, Ludwig Monika, Hagel Alexander F., Schildberg Claus W., Veits Lothar, Gyvyte Ugne, Weise Katharina, Schueller Vitalia, Boehmer Anne C., Schroeder Julia, Gehlen Jan, Kreuser Nicole, Hofer Sebastian, Lang Hauke, Lordick Florian, Malfertheiner Peter, Moehler Markus, Pech Oliver, Vassos Nikolaos, Rodermann Ernst, Izbicki Jakob R., Kruschewski Martin, Ott Katja, Schumann Ralf R., Vieth Michael, Mangold Elisabeth, Gasenko Evita, Kupcinskis Limas, Brenner Hermann, Grinuninger Peter, Bujanda Luis, Sopena Federico, Espinel Jesus, Thomson Concha, Perez-Aisa Angeles, Campo Rafael, Geijo Fernando, Collette Daniela, Bruns Christiane, Messerle Katharina, Gockel Ines, Noethen Markus M., Lippert Hans, Ridwelski Karsten, Lanas Angel, Keller Gisela, Knapp Michael, Leja Marcis, Kupcinskis Juozas, Garcia-Gonzalez Maria A., Venerito Marino, Schumacher Johannes

Evidence for PTGER4, PSCA, and MBOAT7 as risk genes for gastric cancer on the genome and transcriptome level

CANCER MEDICINE. 2018; 7(10): 5057-5065. Article

Holch Julian Walter, Ricard Ingrid, Stintzing Sebastian, von Weikersthal Ludwig Fischer, Decker Thomas, Kiani Alexander, Vehling-Kaiser Ursula, Al-Batran Salah-Eddin, Heintges Tobias, Lerchenmueller Christian, Kahl Christoph, Kullmann Frank, Scheithauer Werner, Scholz Michael, Mueller Sebastian, Link Hartmut, Rost Andreas, Hoeffkes Heinz-Gert, Moehler Markus, Lindig Reinhard Udo, Miller-Phillips Lisa, Kirchner Thomas, Jung Andreas, von Einem Jobst Christian, Modest Dominik Paul, Heinemann Volker

Relevance of liver-limited disease in metastatic colorectal cancer: Subgroup findings of the FIRE-3/AIO KRK0306 trial

INTERNATIONAL JOURNAL OF CANCER. 2018; 142(5): 1047-1055. Article

Lyros Orestis, Thomaidis Thomas, Mueller Manuel, Sivanathan Visva, Grimminger Peter, Lang Hauke, Gockel Ines, Hartmann Joerg T., Moehler Markus

External Validation of the Proposed Kiel Staging System and Comparison with the Old (6th Edition) and the Currently Used (7th Edition) TNM Classification in Gastric Cancer

ONCOLOGY RESEARCH AND TREATMENT. 2018; 41(3): 122-128. Article

Miller-Phillips L., von Weikersthal L. Fischer, Kaiser F., Al-Batran S-E., Heintges T., Neureiter D., Kahl C., Kullmann F., Moehler M., Scheithauer W., Vazart C., Fontaine K., Held S., Modest D. P., Neumann J., Jung A., Kirchner T., Heinemann V., Stintzing S.

Association of microRNA-21 (miR-21) with efficacy of cetuximab (cet) and bevacizumab (bev) in patients with metastatic colorectal cancer (mCRC) within the FIRE-3 study (AIO KRK-0306)

ANNALS OF ONCOLOGY. 2018; 29: 39-39. Meeting Abstract

Moehler M.

Immuno-Oncology in gastric cancer: Soon standard? If so, for whom and when?

ONCOLOGY RESEARCH AND TREATMENT. 2018; 41: 268-268. Meeting Abstract

Moehler M., Maderer A., Lordick F., Tannapfel A., Kanzler S., Hoehler T., Thuss-Patience P., Moenig S., Meyer H. -J., Wilke H., Stahl M. K.

Perioperative chemotherapy plus +/- EGFR inhibition in unselected patients with locally advanced esophagogastric cancer: a randomized phase II study with a large advanced biomarker program of the German Cancer Society (AIO/CAO STO-0801)

ONCOLOGY RESEARCH AND TREATMENT. 2018; 41: 69-69. Meeting Abstract

Moehler M., Maderer A., Thuss-Patience P., Brenner B., Hecker J., Longo Munoz F., Meiler J., Ettrich T., Hofheinz R., Al-Batran S., Vogel A., Mueller L., Lutz M., Borchert K., Greil R., Alsina M., Karatas A., Van Cutsem E., Keller R., Larcher-Senn J., Lorenzen S.

Cisplatin/5-fluorouracil plus +/- panitumumab for patients with non-resectable, advanced or metastatic esophageal squamous cell cancer: A randomized phase III AIO/EORTC trial with an extensive biomarker program

ANNALS OF ONCOLOGY. 2018; 29. Meeting Abstract

Moehler Markus

Immunotherapy in Gastrointestinal Carcinoma - How to Separate Hope from Hype

ONCOLOGY RESEARCH AND TREATMENT. 2018; 41(5): 264-265. Editorial Material

Moehler Markus, Goepfert Katrin, Lenz Heinz-Josef

Outlook: Immunotherapy in Gastrointestinal Carcinoma - Innovative Strategies

ONCOLOGY RESEARCH AND TREATMENT. 2018; 41(5): 313-315. Review

Datensatz in Web of Science®

Moehler Markus, Schad Arno, Maderer Annett, Atasoy Ajlan, Mauer Murielle E., Caballero Carmela, Thomaidis Thomas, John Jestinah M. Mahachie, Lang Istvan, Van Cutsem Eric, Freire Joao, Lutz Manfred P., Roth Arnaud

Lapatinib with ECF/X in the first-line treatment of metastatic gastric cancer according to HER2neu and EGFR status: a randomized placebo-controlled phase II study (EORTC 40071)

CANCER CHEMOTHERAPY AND PHARMACOLOGY. 2018; 82(4): 733-739. Article

Datensatz in Web of Science®

Moehler Markus H., Janjigian Yelena Yuriy, Adenis Antoine, Aucoin Jean-Sebastien, Boku Narikazu, Chau Ian, Cleary James M., Feeney Kynan, Franke Fabio A., Mendez Guillermo Ariel, Schenker Michael, Li Mingshun, Hitre Erika, Couture Felix, Karamouzis Michalis, Etienne Pierre-Luc, Ajani Jaffer A.

CheckMate 649: A randomized, multicenter, open-label, phase III study of nivolumab (NIVO) plus ipilimumab (IPI) or nivo plus chemotherapy (CTX) versus CTX alone in patients with previously untreated advanced (Adv) gastric (G) or gastroesophageal junction (GEJ) cancer.

JOURNAL OF CLINICAL ONCOLOGY. 2018; 36(4). Meeting Abstract

Moehler Markus H., Ryu Min-Hee, Lee Keun-Wook, Coskun Hasan Senol, Wong Rachel, Ozguroglu Mustafa, Chung Hyun-Choel, Poltoratsky Artem, Tsuji Akihito, Yen Chia-Jui, Muntean Alina, le Sourd Samuel, Vaccaro Gina M., Taieb Julien, Boku Narikazu, Sharma Maitreyi, Xiong Huiling, Conti Ilaria, Bang Yung-Jue

JAVELIN Gastric 100: Phase 3 trial of avelumab (anti-PD-L1) maintenance therapy versus continuation of first-line chemotherapy in patients with advanced gastric or gastroesophageal junction cancer (GC/GEJC).

JOURNAL OF CLINICAL ONCOLOGY. 2018; 36(4). Meeting Abstract

Proebstle Thomas M., Kleis-Fischer Bettina, Moehler Thomas, Goeckeritz Oliver, Franklin Ian J., Almeida Jose I.

A two-cohort feasibility study on polyglycolic acid yarn implantation for abolition of saphenous vein reflux

JOURNAL OF VASCULAR SURGERY-VEIN AND LYMPHATIC DISORDERS. 2018; 6(1): 41-+. Article; Proceedings Paper

Schoenherr C., Goetze T., Reichart A., Hausen G. Zur, Pauligk C., Schoettker B., Siegler G., Doerfel S., Aldaoud A., Schubert J., Homann N., Hoeffkes H., Schnell R., Koenigsmann M., Blau W., Uhlig J., Kunzmann V., Trojan J., Moehler M., Al-Batran S. -E.

Metastatic Pancreatic Cancer: Real Life Data from the German Quality of Life and Translational Research on Pancreatic Cancer Study (Qolixane)

ONCOLOGY RESEARCH AND TREATMENT. 2018; 41: 61-61. Meeting Abstract

Schwaegermann M. -K., Hess G., Theobald M., Pretzell I., Moehler M.

The informed consent process for oncological treatment: patients' understanding and satisfaction - a prospective evaluation

ONCOLOGY RESEARCH AND TREATMENT. 2018; 41: 141-141. Meeting Abstract

Sivanathan Visvakanth, Stahl Michael, Utz Christoph, Maderer Annett, Lordick Florian, Mihaljevic Andre, Kanzler Stephan, Hoehler Thomas, Thuss-Patience Peter, Moenig Stefan, Kunzmann Volker, Schroll Sebastian, Sandermann Andreas, Tannapfel Andrea, Meyer Hans-Joachim, Schuhmacher Christoph, Wilke Hans Jochen, Krause Katrin, Moehler Markus
Predictive Significance of endosonographic (EUS) Staging in locally advanced gastric Adenocarcinoma of the Stomach (MC) or esophagogastric Junction (AEG)-Analysis of Data from a perioperative AIO-CAO Phase II Study
INTERNIST. 2018; 59: S43-S44. Meeting Abstract

Stein Alexander, Moehler Markus, Trojan Joerg, Goekkurt Eray, Vogel Arndt
Immuno-oncology in GI tumours: Clinical evidence and emerging trials of PD-1/PD-L1 antagonists
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY. 2018; 130: 13-26. Review

Stintzing S., Lenz H. -J., Neureiter D., von Weikersthal L. F., Al-Batran S. -E., Heintges T., Lerchenmueller C., Kahl C., Seipelt G., Kullmann F., Vehling-Kaiser U., Moehler M., Scheithauer W., Held S., Modest D. P., Jung A., Kirchner T., Wirapati P., Tejpar S., Heinemann V.
Consensus molecular subgroups (CMS) of colorectal cancer (CRC) and 1st-line efficacy of FOLFIRI plus cetuximab or bevacizumab in the FIRE-3 (AIO KRK-0306) trial
ONCOLOGY RESEARCH AND TREATMENT. 2018; 41: 8-9. Meeting Abstract

Taieb Julien, Moehler Markus, Boku Narikazu, Ajani Jaffer A., Ruiz Eduardo Yanez, Ryu Min-Hee, Guenther Silke, Chand Vikram, Bang Yung-Jue
Evolution of checkpoint inhibitors for the treatment of metastatic gastric cancers: Current status and future perspectives
CANCER TREATMENT REVIEWS. 2018; 66: 104-113. Review

Talukdar Fazlur Rahman, di Pietro Massimiliano, Secrier Maria, Moehler Markus, Goepfert Katrin, Coelho Lima Sheila Soares, Ribeiro Pinto Luis Felipe, Hendricks Denver, Parker Mohamed Iqbal, Herceg Zdenko
Molecular landscape of esophageal cancer: implications for early detection and personalized therapy
ANNALS OF THE NEW YORK ACADEMY OF SCIENCES. 2018; 1434(1): 342-359. Review

Vogel Arndt, Kasper Stefan, Bitzer Michael, Block Andreas, Sinn Marianne, Schulze-Bergkamen Henning, Moehler Markus, Pfarr Nicole, Endris Volker, Goepfert Benjamin, Merx Kirsten, Schnoy Elisabeth, Siveke Jens T., Michl Patrick, Waldschmidt Dirk, Kuhlmann Jan, Geissler Michael, Kahl Christoph, Evenkamp Ralph, Schmidt Torben, Kuhlmann Alexander, Weichert Wilko, Kubicka Stefan
PICCA study: panitumumab in combination with cisplatin/gemcitabine chemotherapy in KRAS wild-type patients with biliary cancer-a randomised biomarker-driven clinical phase II AIO study
EUROPEAN JOURNAL OF CANCER. 2018; 92: 11-19. Article

Al-Batran Salah-Eddin, Homann Nils, Pauligk Claudia, Illerhaus Gerald, Martens Uwe M., Stoehlmacher Jan, Schmalenberg Harald, Luley Kim B., Prasnikar Nicole, Egger Matthias, Probst Stephan, Messmann Helmut, Moehler Markus, Fischbach Wolfgang, Hartmann Joerg T., Mayer Frank, Hoeffkes Heinz-Gert, Koenigsmann Michael, Arnold Dirk, Kraus Thomas W., Grimm Kersten, Berkhoff Stefan, Post Stefan, Jager Elke, Bechstein Wolf, Ronellenfitsch Ulrich, Moenig Stefan, Hofheinz Ralf D.
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer The AIO-FLOT3 Trial
JAMA ONCOLOGY. 2017; 3(9): 1237-1244. Article

Bang Yung-Jue, Cho Jae Yong, Kim Yeul Hong, Kim Jin Won, Di Bartolomeo Maria, Ajani Jaffer A., Yamaguchi Kensei, Balogh Agnes, Sanchez Teresa, Moehler Markus
Efficacy of Sequential Ipilimumab Monotherapy versus Best Supportive Care for Unresectable Locally Advanced/Metastatic Gastric or Gastroesophageal Junction Cancer
CLINICAL CANCER RESEARCH. 2017; 23(19): 5671-5678. Article

Heinrich B., Klein J., Delic M., Goepfert K., Engel V., Geberzahn L., Lusky M., Erbs P., Preville X., Moehler M.
Immunogenicity of oncolytic vaccinia viruses JX-GFP and TG6002 in a human melanoma in vitro model: studying immunogenic cell death, dendritic cell maturation and interaction with cytotoxic T lymphocytes
ONCOTARGETS AND THERAPY. 2017; 10: 2389-2401. Article

Kataoka Kozo, Kinoshita Takahiro, Moehler Markus, Mauer Murielle, Shitara Kohei, Wagner Anna Dorothea, Schrauwen Stefanie, Yoshikawa Takaki, Roviello Franco, Tokunaga Masanori, Boku Narikazu, Ducreux Michel, Terashima Masanori, Lordick Florian
Current management of liver metastases from gastric cancer: what is common practice? New challenge of EORTC and JCOG
GASTRIC CANCER. 2017; 20(5): 904-912. Article

Lordick Florian, Al-Batran Salah-Eddin, Dietel Manfred, Gaiser Timo, Hofheinz Ralf-Dieter, Kirchner Thomas, Kreipe Hans H., Lorenzen Sylvie, Moehler Markus, Quaas Alexander, Roecken Christoph, Rueschoff Josef, Tannapfel Andrea, Thuss-Patience Peter, Baretton Gustavo
HER2 testing in gastric cancer: results of a German expert meeting
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY. 2017; 143(5): 835-841. Review

McNamara Mairead Geraldine, Bridgewater John, Lopes Andre, Wasan Harpreet, Malka David, Jensen Lars Henrik, Okusaka Takuji, Knox Jennifer J., Wagner Dorothea, Cunningham David, Shannon Jenny, Goldstein David, Moehler Markus, Bekaii-Saab Tanios, Valle Juan W.
Systemic therapy in younger and elderly patients with advanced biliary cancer: sub-analysis of ABC-02 and twelve other prospective trials
BMC CANCER. 2017; 17. Article

Metzger Jan-Christopher, Wollschlaeger Daniel, Miederer Matthias, Vaupel Peter, Moehler Markus, Schmidberger Heinz, Mayer Arnulf
Inclusion of PET-CT into planning of primary or neoadjuvant chemoradiotherapy of esophageal cancer improves prognosis
STRAHLENTHERAPIE UND ONKOLOGIE. 2017; 193(10): 791-799. Article

Modest D. P., Ricard I., Stintzing S., von Weikersthal L. Fischer, Decker T., Kiani A., Vehling-Kaiser U., Al-Batran S-E., Heintges T., Kahl C., Seipelt G., Kullmann F., Scheithauer W., Moehler M., Westphalen C. B., Holch J. W., von Einem J. C., Held S., Heinemann V.
Evaluation of survival across several treatment lines in metastatic colorectal cancer: Analysis of the FIRE-3 trial (AIO KRK0306)
EUROPEAN JOURNAL OF CANCER. 2017; 84: 262-269. Article

Modest Dominik P., Stintzing Sebastian, Von Weikersthal Ludwig Fischer, Decker Thomas, Kiani Alexander, Vehling-Kaiser Ursula, Al-Batran Salah-Eddin, Heintges Tobias, Lerchenmueller Christian,

Kahl Christoph, Seipelt Gernot, Kullmann Frank, Scheithauer Werner, Kirchner Thomas, Jung Andreas, Stauch Martina, von Einem Jobst Christian, Moehler Markus, Held Swantje, Heinemann Volker
Relation of early tumor shrinkage (ETS) observed in first-line treatment to efficacy parameters of subsequent treatment in FIRE-3 (AIOKRK0306)

INTERNATIONAL JOURNAL OF CANCER. 2017; 140(8): 1918-1925. Article

Modest Dominik Paul, Stintzing Sebastian, von Weikersthal Ludwig Fischer, Decker Thomas, Kiani Alexander, Vehling-Kaiser Ursula, Al-Batran Salah-Eddin, Heintges Tobias, Kahl Christoph, Seipelt Gernot, Kullmann Frank, Scheithauer Werner, Moehler Markus, Holch Julian Walter, von Einem Jobst Christian, Held Swantje, Heinemann Volker

Exploring the effect of primary tumor sidedness on therapeutic efficacy across treatment lines in patients with metastatic colorectal cancer: analysis of FIRE-3 (AIOKRK0306)

ONCOTARGET. 2017; 8(62): 105749-105760. Article

Moehler Markus, Mahlberg Rolf, Heinemann Volker, Obermannova Radka, Kubala Eugen, Melichar Bohuslav, Weinmann Arndt, Scigalla Paul, Tesarova Marietta, Janda Petr, Hedouin-Biville Fabienne, Mansoor Wasat

Phase I study of orally administered S-1 in combination with epirubicin and oxaliplatin in patients with advanced solid tumors and chemotherapy-naïve advanced or metastatic esophagogastric cancer
GASTRIC CANCER. 2017; 20(2): 358-367. Article

Rades Dirk, Maderer Annett, Panzner Annika, Hunold Peter, Sivanathan Visvakanth, Schmidberger Heinz, Moehler Markus H.

Phase I Study of Definitive Radio-chemotherapy with Cisplatin, 5-Fluorouracil and Cetuximab for Unresectable Locally Advanced Esophageal Cancer

ANTICANCER RESEARCH. 2017; 37(5): 2703-2708. Article

Schimanski Carl Christoph, Staib Frank, Goehler Thomas, Hebart Holger, Heike Michael, Neise Michael, Rudi Jochen, Geer Thomas, Dingeldein Gerrit, Lang Claudia, Ehscheidt Peter, Flohr Thomas, Josten Klaus Maria, Karthaus Meinolf, Schmittel Alexander, Wierecky Jan, Boller Emil, Indorf Martin, Woerns Marcus-Alexander, Galle Peter R., Moehler Markus

Dermatux: phase IV trial of Cetuximab plus FOLFIRI in first-line metastatic colorectal cancer receiving a pre-defined skin care

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY. 2017; 143(6): 1023-1034. Article

Stintzing S., Miller-Phillips L., Modest D. P., von Weikersthal L. Fischer, Decker T., Kiani A., Vehling-Kaiser U., Al-Batran S-E., Heintges T., Kahl C., Seipelt G., Kullmann F., Stauch M., Scheithauer W., Held S., Moehler M., Jagenburg A., Kirchner T., Jung A., Heinemann V.

Impact of BRAF and RAS mutations on first-line efficacy of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab: analysis of the FIRE-3 (AIO KRK-0306) study

EUROPEAN JOURNAL OF CANCER. 2017; 79: 50-60. Article

Ungerechts Guy, Engeland Christine E., Buchholz Christian J., Eberle Juergen, Fechner Henry, Geletneky Karsten, Holm Per Sonne, Kreppel Florian, Kuehnel Florian, Lang Karl Sebastian, Leber Mathias F., Marchini Antonio, Moehler Markus, Muehlebach Michael D., Rommelaere Jean, Springfield Christoph, Lauer Ulrich M., Nettelbeck Dirk M.

Virotherapy Research in Germany: From Engineering to Translation

HUMAN GENE THERAPY. 2017; 28(10): 800-819. Review

Venerito Marino, Weise Friederike, Goni Elisabetta, Reinhold Dirk, Ridwelski Karsten, Lingohr Philipp, Matthaehanno, Schildberg Claus, Kruschewski Martin, Krasniuk Iurii, Grimminger Peter P., Moehler Markus, Wolff Stefanie, Lippert Hans, Vieth Michael, Veits Lothar, Bruns Christiane, Lordick Florian, Gockel Ines, Malfertheiner Peter, Schumacher Johannes
GASTRIC CANCER IN AUTOIMMUNE GASTRITIS: A CASE-CONTROL STUDY FROM THE STAR PROJECT ON GASTRIC CANCER RESEARCH
GASTROENTEROLOGY. 2017; 152(5): S1028-S1028. Meeting Abstract

Wagner Anna Dorothea, Syn Nicholas L. X., Moehler Markus, Grothe Wilfried, Yong Wei Peng, Tai Bee-Choo, Ho Jingshan, Unverzagt Susanne
Chemotherapy for advanced gastric cancer
COCHRANE DATABASE OF SYSTEMATIC REVIEWS. 2017; (8). Review

Alsina Maria, Moehler Markus, Hierro Cinta, Guardeno Raquel, Tabernero Josep
Immunotherapy for Gastric Cancer: A Focus on Immune Checkpoints
TARGETED ONCOLOGY. 2016; 11(4): 469-477. Review

Baretton G., Dietel M., Gaiser T., Kirchner T., Kreipe H. H., Quaas A., Roeken C., Rueschoff J., Tannapfel A., Lordick F., Al-Batran S., Hofheinz R., Lorenzen S., Moehler M., Thuss-Patience P.
HER2 testing in gastric cancer. Results of a meeting of German experts
PATHOLOGIE. 2016; 37(4): 361-366. Article

Becker Jessica, May Andrea, Gerges Christian, Anders Mario, Schmidt Claudia, Veits Lothar, Noder Tania, Mayershofer Rupert, Kreuser Nicole, Manner Hendrik, Venerito Marino, Hofer Jan-Hinnerk, Lyros Orestis, Ahlbrand Constantin J., Arras Michael, Hofer Sebastian, Heinrichs Sophie K. M., Weise Katharina, Hess Timo, Boehmer Anne C., Kosiol Nils, Kiesslich Ralf, Izbicki Jakob R., Hoelscher Arnulf H., Bollschweiler Elfriede, Malfertheiner Peter, Lang Hauke, Moehler Markus, Lorenz Dietmar, Ott Katja, Schmidt Thomas, Noethen Markus M., Hackelsberger Andreas, Schumacher Brigitte, Pech Oliver, Vashist Yogesh, Vieth Michael, Weismueller Josef, Knapp Michael, Neuhaus Horst, Roesch Thomas, Ell Christian, Gockel Ines, Schumacher Johannes
The Barrett-associated variants at GDF7 and TBX5 also increase esophageal adenocarcinoma risk
CANCER MEDICINE. 2016; 5(5): 888-891. Article

Bridgewater J., Lopes A., Wasan H., Malka D., Jensen L., Okusaka T., Knox J., Wagner D., Cunningham D., Shannon J., Goldstein D., Moehler M., Bekaii-Saab T., McNamara M. G., Valle J. W.
Prognostic factors for progression-free and overall survival in advanced biliary tract cancer
ANNALS OF ONCOLOGY. 2016; 27(1): 134-140. Article

Gockel Ines, Niebisch Stefan, Ahlbrand Constantin Johannes, Hoffmann Christian, Moehler Markus, Dueber Christoph, Lang Hauke, Heid Florian
Risk and Complication Management in Esophageal Cancer Surgery: A Review of the Literature
THORACIC AND CARDIOVASCULAR SURGEON. 2016; 64(7): 596-605. Review

Lorenzen S., Arnold D., Fottner C., Leichsenring J., Moehler M., Seufferlein T., Vogel A., Weber M. M., Reinacher-Schick A.
ASCO-update 2015-highlights of the 51. meeting of the american society of clinical oncology/ASCO 2015
ZEITSCHRIFT FUR GASTROENTEROLOGIE. 2016; 54(2): 167-172. Review

Lutz Manfred P., Zalberg John R., Glynne-Jones Rob, Ruers Theo, Ducreux Michel, Arnold Dirk, Aust Daniela, Brown Gina, Bujko Krzysztof, Cunningham Christopher, Evrard Serge, Folprecht Gunnar, Gerard Jean-Pierre, Habr-Gama Angelita, Haustermans Karin, Holm Torbjorn, Kuhlmann Koert F., Lordick Florian, Mentha Gilles, Moehler Markus, Nagtegaal Iris D., Pigazzi Alessio, Pucciarelli Salvatore, Roth Arnaud, Rutten Harm, Schmoll Hans-Joachim, Sorbye Halfdan, Van Cutsem Eric, Weitz Juergen, Otto Florian

2nd St. Gallen EORTC Gastrointestinal Cancer Conference: Consensus recommendations on controversial issues in the primary treatment of rectal cancer (vol 63, pg 11, 2016)
EUROPEAN JOURNAL OF CANCER. 2016; 68: 208-209. Correction

Lutz Manfred P., Zalberg John R., Glynne-Jones Rob, Ruers Theo, Ducreux Michel, Arnold Dirk, Aust Daniela, Brown Gina, Bujko Krzysztof, Cunningham Christopher, Evrard Serge, Folprecht Gunnar, Gerard Jean-Pierre, Habr-Gama Angelita, Haustermans Karin, Holm Torbjorn, Kuhlmann Koert F., Lordick Florian, Mentha Gilles, Moehler Markus, Nagtegaal Iris D., Pigazzi Alessio, Pucciarelli Salvatore, Roth Arnaud, Rutten Harm, Schmoll Hans-Joachim, Sorbye Halfdan, Van Cutsem Eric, Weitz Juergen, Otto Florian

Second St. Gallen European Organisation for Research and Treatment of Cancer Gastrointestinal Cancer Conference: consensus recommendations on controversial issues in the primary treatment of rectal cancer
EUROPEAN JOURNAL OF CANCER. 2016; 63: 11-24. Review

Martchenko Ksenia, Schmidtmann Irene, Thomaidis Thomas, Thole Verena, Galle Peter R., Becker Marc, Moehler Markus, Wehler Thomas C., Schimanski Carl C.

Last line therapy with sorafenib in colorectal cancer: A retrospective analysis
WORLD JOURNAL OF GASTROENTEROLOGY. 2016; 22(23): 5400-5405. Article

McNamara Mairead G., Bridgewater John A., Lopes Andre, Wasan Harpreet, Malka David, Jensen Henrik R., Okusaka Takuji, Knox Jennifer J., Wagner Anna Dorothea, Cunningham David, Shannon Jenny, Goldstein David, Moehler Markus H., Bekaii-Saab Tanios S., Valle Juan W.

Systemic therapy in elderly patients with advanced biliary tract cancer: Sub-analysis of ABC-02 and 10 other prospective studies.

JOURNAL OF CLINICAL ONCOLOGY. 2016; 34(4). Meeting Abstract

Modest Dominik Paul, Stintzing Sebastian, von Weikersthal Ludwig Fischer, Sobrero Alberto F., Decker Thomas, Kiani Alexander, Vehling-Kaiser Ursula, Al-Batran Salah-Eddin, Heintges Tobias, Seipelt Gernot, Lerchenmuller Christian A., Kahl Christoph, Kullmann Frank, Stauch Martina, Scheithauer Werner, Held Swantje, Moehler Markus H., Jung Andreas, Kirchner Thomas, Heinemann Volker

Time-course evaluation of survival and treatment in FIRE-3 (AIO KRK0306, first-line therapy of KRAS wild-type metastatic colorectal cancer with FOLFIRI plus cetuximab or bevacizumab).

JOURNAL OF CLINICAL ONCOLOGY. 2016; 34(4). Meeting Abstract

Moehler Markus, Delic Maike, Goepfert Katrin, Aust Daniela, Grabsch Heike I., Halama Niels, Heinrich Bernd, Julie Catherine, Lordick Florian, Lutz Manfred P., Mauer Murielle, Alsina Maqueda Maria, Schild Hansjoerg, Schimanski Carl C., Wagner Anna-Dorothea, Roth Arnaud, Ducreux Michel

Immunotherapy in gastrointestinal cancer: Recent results, current studies and future perspectives

EUROPEAN JOURNAL OF CANCER. 2016; 59: 160-170. Review

Moehler Markus, Gepfner-Tuma Irina, Maderer Annett, Thuss-Patience Peter C., Ruessel Joern, Hegewisch-Becker Susanna, Wilke Hansjochen, Al-Batran Salah-Eddin, Rafiyan Mohammad-Reza, Weissinger Florian, Schmoll Hans-Joachim, Kullmann Frank, von Weikersthal Ludwig Fischer, Siveke Jens T., Weusmann Jens, Kanzler Stephan, Schimanski Carl Christoph, Otte Melanie, Schollenberger Lukas, Koenig Jochem, Galle Peter R.
Sunitinib added to FOLFIRI versus FOLFIRI in patients with chemorefractory advanced adenocarcinoma of the stomach or lower esophagus: a randomized, placebo-controlled phase II AIO trial with serum biomarker program
BMC CANCER. 2016; 16. Article

Oh Do-Youn, Lockhart Albert C., Wong Deborah Jean Lee, Taylor Matthew Hiram, Bajars Marcis, von Heydebreck Anja, Moehler Markus H., Safran Howard
Avelumab (MSB0010718C), an anti-PD-L1 antibody, as a third-line treatment in patients with advanced gastric or gastroesophageal junction cancer: A phase Ib JAVELIN Solid Tumor trial.
JOURNAL OF CLINICAL ONCOLOGY. 2016; 34(4). Meeting Abstract

Proebstle Thomas M., Moehler Thomas
Regarding "A longitudinal single-center cohort study on the prevalence and risk of accessory saphenous vein reflux after radiofrequency segmental thermal ablation of great saphenous veins"
Reply
Journal of Vascular Surgery-Venous and Lymphatic Disorders. 2016; 4(3): 380-381. Letter

Rey J. W., Deris N., Marquardt J. U., Thomaidis T., Moehler M., Kittner J. M., Nguyen-Tat M., Duemcke S., Tresch A., Biesterfeld S., Goetz M., Mudter J., Neurath M. F., Galle P. R., Kiesslich R., Hoffman A.
High-definition endoscopy with iScan and Lugol's solution for the detection of inflammation in patients with nonerosive reflux disease: histologic evaluation in comparison with a control group
DISEASES OF THE ESOPHAGUS. 2016; 29(2): 185-191. Article

Stintzing Sebastian, Modest Dominik P., Rossius Lisa, Lerch Markus M., von Weikersthal Ludwig Fischer, Decker Thomas, Kiani Alexander, Vehling-Kaiser Ursula, Al-Batran Salah-Eddin, Heintges Tobias, Lerchenmueller Christian, Kahl Christoph, Seipelt Gernot, Kullmann Frank, Stauch Martina, Scheithauer Werner, Held Swantje, Giessen-Jung Clemens, Moehler Markus, Jagenburg Andreas, Kirchner Thomas, Jung Andreas, Heinemann Volker
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial
LANCET ONCOLOGY. 2016; 17(10): 1426-1434. Article

Al-Batran S. E., Kroening H., Hannig C. V., Hamm T., Moorahrend E., Petersen V., Eggers E., Hempel D., Zielke K., Thuss-Patience P., Moehler M., Hegewisch-Becker S.
Trastuzumab in combination with different first-line chemotherapies for treatment of HER2-positive metastatic gastric or gastro-oesophageal junction cancer: Updated findings from the German non-interventional study HerMES
EUROPEAN JOURNAL OF CANCER. 2015; 51: S444-S444. Meeting Abstract

Becker Jessica, May Andrea, Gerges Christian, Anders Mario, Veits Lothar, Weise Katharina, Czamara Darina, Lyros Orestis, Manner Hendrik, Terheggen Grischa, Venerito Marino, Noder Tania, Mayershofer Rupert, Hofer Jan-Hinnerk, Karch Hans-Werner, Ahlbrand Constantin J., Arras Michael,

Hofer Sebastian, Mangold Elisabeth, Heilmann-Heimbach Stefanie, Heinrichs Sophie K. M., Hess Timo, Kiesslich Ralf, Izbicki Jakob R., Hoelscher Arnulf H., Bollschweiler Elfriede, Malfertheiner Peter, Lang Hauke, Moehler Markus, Lorenz Dietmar, Mueller-Myhsok Bertram, Ott Katja, Schmidt Thomas, Whiteman David C., Vaughan Thomas L., Noethen Markus M., Hackelsberger Andreas, Schumacher Brigitte, Pech Oliver, Vashist Yogesh, Vieth Michael, Weismueller Josef, Neuhaus Horst, Roesch Thomas, Ell Christian, Gockel Ines, Schumacher Johannes
Supportive evidence for FOXP1, BARX1, and FOXF1 as genetic risk loci for the development of esophageal adenocarcinoma
CANCER MEDICINE. 2015; 4(11): 1700-1704. Article

Gockel I, Niebisch S, Ahlbrand CJ, Hoffmann C, Möhler M, Düber C, Lang H, Heid F
Risk and Complication Management in Esophageal Cancer Surgery: A Review of the Literature
[http://dx.doi.org/ 10.1055/s-0034-1399763](http://dx.doi.org/10.1055/s-0034-1399763) 2015

Modest Dominik P., Stintzing Sebastian, von Weikersthal Ludwig Fischer, Decker Thomas, Kiani Alexander, Vehling-Kaiser Ursula, Al-Batran Salah-Eddin, Heintges Tobias, Lerchenmueller Christian, Kahl Christoph, Seipelt Gernot, Kullmann Frank, Stauch Martina, Scheithauer Werner, Held Svantje, Moehler Markus, Jung Andreas, Kirchner Thomas, Heinemann Volker
Impact of Subsequent Therapies on Outcome of the FIRE-3/AIO KRK0306 Trial: First-Line Therapy With FOLFIRI Plus Cetuximab or Bevacizumab in Patients With KRAS Wild-Type Tumors in Metastatic Colorectal Cancer
JOURNAL OF CLINICAL ONCOLOGY. 2015; 33(32): 3718-+. Article

Moehler M., Ehrlich A., Ruckes C., Thomaidis T., Weinmann A., Galle P. R., Woerns M. A.
Safety and efficacy of Afatinib with Gemcitabine/Cisplatin in chemo-naive patients with metastatic biliary tract cancer: An open-label, uncontrolled phase Ib trial
EUROPEAN JOURNAL OF CANCER. 2015; 51: S440-S440. Meeting Abstract

Moehler M., Melichar B., Obermannova R., Weinmann A., Scigalla P., Kubala E., Mahlberg R., Heinemann V., Tesarova M., Janda P., Biville F., Mansoor W.
S-1 in combination with epirubicin and oxaliplatin (EOS) in Caucasian patients (pts) with advanced or metastatic gastric cancer (AGC): Results of a phase I study
ANNALS OF ONCOLOGY. 2015; 26. Meeting Abstract

Moehler Markus, Baltin Christoph T. H., Ebert Matthias, Fischbach Wolfgang, Gockel Ines, Grenacher Lars, Hoelscher Arnulf H., Lordick Florian, Malfertheiner Peter, Messmann Helmut, Meyer Hans-Joachim, Palmqvist Anne, Roecken Christoph, Schuhmacher Christoph, Stahl Michael, Stuschke Martin, Vieth Michael, Wittekind Christian, Wagner Dorothea, Moenig Stefan P.
International comparison of the German evidence-based S3-guidelines on the diagnosis and multimodal treatment of early and locally advanced gastric cancer, including adenocarcinoma of the lower esophagus
GASTRIC CANCER. 2015; 18(3): 550-563. Article

Moehler Markus, Thomaidis Thomas, Zeifri Chourouk, Barhoom Tareq, Marquardt Jens, Ploch Philippe, Schattenberg Joern, Maderer Annett, Schimanski Carl Christoph, Weinmann Arndt, Woerns Marcus Alexander, Kranich Anne L., Warnecke Jens M., Galle Peter Robert
Inclusion of targeted therapies in the standard of care for metastatic colorectal cancer patients in a German cancer center: the more the better?!
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY. 2015; 141(3): 515-522. Article

Moehler Markus H., Lordick Florian, Mihaljevic Andre L., Kanzler Stephan, Hoehler Thomas, Thuss-Patience Peter C., Moenig Stefan Paul, Kunzmann Volker, Schroll Sebastian, Meyer Hans-Joachim, Sandermann Andreas, Schumacher Christoph, Wilke Hansjochen, Tannapfel Andrea, Stahl Michael
The role of panitumumab in combination with ECX in perioperative chemotherapy of unselected patients with locally advanced gastroesophageal adenocarcinomas: Randomized phase II study of the German Cancer Society

JOURNAL OF CLINICAL ONCOLOGY. 2015; 33(15). Meeting Abstract

Moehler Markus Hermann, Heinemann Volker, Obermannova Radka, Kubala Eugen, Melichar Bohuslav, Mahlberg Rolf, Weinmann Arndt, Scigalla Paul, Tesarova Marietta, Janda Petr, Biville-Hedouin Fabienne, Mansoor Wasat

A phase I, dose-finding study of orally administered S-1 in combination with epirubicin and oxaliplatin (EOS) in patients (pts) with advanced or metastatic gastrointestinal cancer (AGIC) and chemonave advanced esophagogastric cancer (AEGC)

JOURNAL OF CLINICAL ONCOLOGY. 2015; 33(3). Meeting Abstract

Moehler Markus Hermann, Schad Arno, Mauer Murielle E., Messina Carlo G. M., John Jestinah. M. Mahachie, Lang Istvan, Van Cutsem Eric, Freire Joao, Lutz Manfred P., Roth Arnaud
Lapatinib combined with ECF/x as first-line metastatic gastric cancer (GC) according to HER2 and EGFR status: A randomized placebo controlled phase II (EORTC 40071)

JOURNAL OF CLINICAL ONCOLOGY. 2015; 33(3). Meeting Abstract

Porschen R., Buck A., Fischbach W., Gockel I., Goerling U., Grenacher L., Hollerbach S., Hoelscher A., Koerber J., Messmann H., Meyer H. J., Miehke S., Moehler M., Noethlings U., Pech U., Schmidberger H., Schmidt M., Stahl M., Stuschke M., Thuss-Patience P., Trojan J., Vanhoefer U., Weimann A., Wenz F., Wullstein C.

S3-Guidelines Diagnosis and Treatment of Squamous Cell Carcinoma and Adenocarcinoma of the Esophagus (Long Version 1.0-September 2015, AWMF-Register Number: 021/023OL)

ZEITSCHRIFT FUR GASTROENTEROLOGIE. 2015; 53(11): 1288-1347. Article

Proebstle Thomas M., Moehler Thomas

A longitudinal single-center cohort study on the prevalence and risk of accessory saphenous vein reflux after radiofrequency segmental thermal ablation of great saphenous veins

JOURNAL OF VASCULAR SURGERY-VENOUS AND LYMPHATIC DISORDERS. 2015; 3(3): 265-269. Article

Stahl Michael, Mihaljevic Andre L., Moehler Markus, Kanzler Stephan, Hoehler Thomas, Thuss-Patience Peter C., Moenig Stefan Paul, Kunzmann Volker, Schroll Sebastian, Lordick Florian, Meyer Hans-Joachim, Sandermann Andreas, Schumacher Christoph, Wilke Hansjochen

Perioperative chemotherapy with ECX plus +/- panitumumab in locally advanced gastroesophageal adenocarcinomas (GEA): A randomized study of the Arbeitsgemeinschaft Internistische Onkologie and the Chirurgische Arbeitsgemeinschaft Onkologie of the German Cancer Society.

JOURNAL OF CLINICAL ONCOLOGY. 2015; 33(3). Meeting Abstract

Stintzing Sebastian, Modest Dominik Paul, von Weikersthal Ludwig Fischer, Decker Thomas, Kiani Alexander, Vehling-Kaiser Ursula, Al-Batran Salah-Eddin, Heintges Tobias, Lerchenmuller Christian A., Kahl Christoph, Seipelt Gernot, Kullmann Frank, Stauch Martina, Scheithauer Werner, Held Swantje, Giessen Clemens Albrecht, Moehler Markus Hermann, Jung Andreas, Kirchner Thomas, Heinemann Volker

Influence of adjuvant pretreatment on outcome of FIRE-3 (AIO KRK-0306): A randomized phase III study of FOLFIRI plus cetuximab or bevacizumab as first-line treatment for wild-type (WT) KRAS (exon 2) metastatic colorectal cancer (mCRC) patients
JOURNAL OF CLINICAL ONCOLOGY. 2015; 33(3). Meeting Abstract

Stintzing Sebastian, von Weikersthal Ludwig Fischer, Decker Thomas, Kiani Alexander, Vehling-Kaiser Ursula, Al-Batran Salah-Eddin, Heintges Tobias, Lerchenmueller Christian, Kahl Christoph, Seipelt Gernot, Kullmann Frank, Stauch Martina, Hielscher Carsten, Held Swantje, Modest Dominik Paul, Moehler Markus H., Scheithauer Werner, Jung Andreas, Kirchner Thomas, Heinemann Volker
Treatment until progression: Data of the "on-treatment" population of the FIRE-3 (AIO KRK-0306) study
JOURNAL OF CLINICAL ONCOLOGY. 2015; 33(15). Meeting Abstract

Vogel Arndt, Kasper Stefan, Weichert Wilko, Bitzer Michael, Block Andreas, Riess Hanno, Schulze-Bergkamen Henning, Moehler Markus H., Merx Kirsten Elisabeth, Endris Volker, Schnoy Elisabeth, Siveke Jens T., Michl Patrick, Waldschmidt Dirk, Kuhlmann Jan, Geissler Michael, Kahl Christoph, Kubicka Stefan
Panitumumab in combination with gemcitabine/cisplatin (GemCis) for patients with advanced KRAS WT biliary tract cancer: A randomized phase II trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO).
JOURNAL OF CLINICAL ONCOLOGY. 2015; 33(15). Meeting Abstract

Wagner Anna Dorothea, Moehler Markus, Grothe Wilfried, Haerting Johannes, Unverzagt Susanne
Novel chemotherapy combinations for metastatic gastric adenocarcinoma (mAGC): An updated meta-analysis
JOURNAL OF CLINICAL ONCOLOGY. 2015; 33(3). Meeting Abstract

Al-Batran S., Kroening H., Hannig C. V., Hamm T., Moorahrend E., Petersen V., Eggers E., Hempel D., Zielke K., Wohlfarth T., Thuss-Patience P. C., Moehler M., Hegewisch-Becker S.
FIRST-LINE CHEMOTHERAPIES FOR TREATMENT OF HER2-POSITIVE METASTATIC GASTRIC CANCER: UPDATED FINDINGS FROM THE GERMAN NON-INTERVENTIONAL STUDY HERMES
ANNALS OF ONCOLOGY. 2014; 25. Meeting Abstract

Goepfert K., Wittmann L., Linnig M., Heinrich B., Galle P., Moehler M.
Impact of CTLA-4 antibodies Tremelimumab and Ipilimumab on the human immune system. Results of an ex vivo human melanoma model with the oncolytic parvovirus H-1 or cytotoxic drugs
ONCOLOGY RESEARCH AND TREATMENT. 2014; 37: 30-30. Meeting Abstract

Heinemann Volker, von Weikersthal Ludwig Fischer, Decker Thomas, Kiani Alexander, Vehling-Kaiser Ursula, Al-Batran Salah-Eddin, Heintges Tobias, Lerchenmueller Christian, Kahl Christoph, Seipelt Gernot, Kullmann Frank, Stauch Martina, Scheithauer Werner, Hielscher Joerg, Scholz Michael, Mueller Sebastian, Link Hartmut, Niederle Norbert, Rost Andreas, Hoeffkes Heinz-Gert, Moehler Markus, Lindig Reinhard U., Modest Dominik P., Rossius Lisa, Kirchner Thomas, Jung Andreas, Stintzing Sebastian
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial
LANCET ONCOLOGY. 2014; 15(10): 1065-1075. Article

Kripp Melanie, Al-Batran Salah-Eddin, Rosowski Johanna, Pauligk Claudia, Homann Nils, Hartmann Jorg Thomas, Moehler Markus, Hofheinz Ralf-Dieter

Quality of life of older adult patients receiving docetaxel-based chemotherapy triplets for esophagogastric adenocarcinoma: a randomized study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)

GASTRIC CANCER. 2014; 17(1): 181-187. Article

Maderer A., Goepfert K., Sauvigny D., Linnig M., Lewis J. D., Galle P. R., Moehler M.

EL102-a new strategy for targeting hypoxia-driven cancer

ONCOLOGY RESEARCH AND TREATMENT. 2014; 37: 32-32. Meeting Abstract

Maderer Annett, Plutizki Stanislav, Kramb Jan-Peter, Goepfert Katrin, Linnig Monika, Khillimberger Katrin, Ganser Christopher, Laueremann Eva, Dannhardt Gerd, Galle Peter R., Moehler Markus

Moguntinones-New Selective Inhibitors for the Treatment of Human Colorectal Cancer

MOLECULAR CANCER THERAPEUTICS. 2014; 13(6): 1399-1409. Article

Moehler M., Maderer A., Schimanski C., Kanzler S., Denzer U., Kolligs F. T., Ebert M. P., Distelrath A., Geissler M., Trojan J., Schuetz M., Berie L., Sauvigny C., Lammert F., Lohse A., Dollinger M. M., Lindig U., Duerr E. M., Lubomierski N., Zimmermann S., Wachtlin D., Kaiser A. -K., Schadmand-Fischer S., Galle P. R., Woerns M.

Gemcitabine plus sorafenib versus gemcitabine alone in advanced biliary tract cancer: A double-blind placebo-controlled multicentre phase II AIO study with biomarker and serum programme

EUROPEAN JOURNAL OF CANCER. 2014; 50(18): 3125-3135. Article

Oue Naohide, Anami Katsuhiko, Schetter Aaron J., Moehler Markus, Okayama Hirokazu, Khan Mohammed A., Bowman Elise D., Mueller Annett, Schad Arno, Shimomura Manabu, Hinoi Takao, Aoyagi Kazuhiko, Sasaki Hiroki, Okajima Masazumi, Ohdan Hideki, Galle Peter R., Yasui Wataru, Harris Curtis C.

High miR-21 expression from FFPE tissues is associated with poor survival and response to adjuvant chemotherapy in colon cancer

INTERNATIONAL JOURNAL OF CANCER. 2014; 134(8): 1926-1934. Article

Stein Alexander, Arnold Dirk, Thuss-Patience Peter C., Moehler Markus, Grothe Wilfried, Seufferlein Thomas, Reinacher-Schick Anke, Geissler Michael, Hofheinz Ralf-Dieter, Schmoll Hans-Joachim

Docetaxel, oxaliplatin and capecitabine (TEX regimen) in patients with metastatic gastric or gastro-esophageal cancer: Results of a multicenter phase I/II study

ACTA ONCOLOGICA. 2014; 53(3): 392-398. Article

Stintzing S., Modest D. P., von Weikersthal L. Fischer, Decker T., Kiani A., Vehling-Kaiser U., Al-Batran S., Heintges T., Lerchenmueller C., Kahl C., Seipelt G., Kullmann F., Scheithauer W., Held S., Giessen C., Moehler M., Jagenburg A., Jung A., Kirchner T., Heinemann V.

INDEPENDENT RADIOLOGICAL EVALUATION OF OBJECTIVE RESPONSE, EARLY TUMOR SHRINKAGE, AND DEPTH OF RESPONSE IN FIRE-3 (AIO KRK-0306) IN THE FINAL RAS EVALUABLE POPULATION

ANNALS OF ONCOLOGY. 2014; 25. Meeting Abstract

Stintzing Sebastian, Jung Andreas, Rossius Lisa, Modest Dominik Paul, von Weikersthal Ludwig Fischer, Decker Thomas, Kiani Alexander, Al-Batran Salah-Eddin, Vehling-Kaiser Ursula, Heintges Tobias, Moehler Markus, Scheithauer Werner, Kirchner Thomas, Heinemann Volker

Mutations within the EGFR signaling pathway: Influence on efficacy in FIRE-3-A randomized phase III study of FOLFIRI plus cetuximab or bevacizumab as first-line treatment for wild-type (WT) KRAS (exon 2) metastatic colorectal cancer (mCRC) patients
JOURNAL OF CLINICAL ONCOLOGY. 2014; 32(3). Meeting Abstract

Thomaidis Thomas, Maderer Annett, Al-Batran Salah-Eddin, Kany Janis, Pauligk Claudia, Steinmetz Kristina, Schad Arno, Hofheinz Ralf, Schmalenberg Harald, Homann Nils, Galle Peter Robert, Moehler Markus
VEGFR-3 and CXCR4 as predictive markers for treatment with fluorouracil, leucovorin plus either oxaliplatin or cisplatin in patients with advanced esophagogastric cancer: a comparative study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)
BMC CANCER. 2014; 14. Article

Thomaidis Thomas, Maderer Annett, Formentini Andrea, Bauer Susanne, Trautmann Mario, Schwarz Michael, Neumann Wiebke, Kittner Jens Martin, Schad Arno, Link Karl-Heinrich, Rey Johannes Wilhelm, Weinmann Arndt, Hoffman Arthur, Galle Peter Robert, Kornmann Marko, Moehler Markus
Proteins of the VEGFR and EGFR pathway as predictive markers for adjuvant treatment in patients with stage II/III colorectal cancer: results of the FOGT-4 trial
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH. 2014; 33. Article

Thomaidis Thomas, Weinmann Arndt, Sprinzl Martin, Kanzler Stephan, Raedle Jochen, Ebert Matthias, Schimanski Carl Cristoph, Galle Peter Robert, Hoehler Thomas, Moehler Markus
Erythropoietin treatment in chemotherapy-induced anemia in previously untreated advanced esophagogastric cancer patients
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY. 2014; 19(2): 288-296. Article

Thomaidis Thomas, Woerns Marcus A., Galle Peter R., Moehler Markus, Schattenberg Joern M.
Treatment of Malignant Ascites with a Second Cycle of Catumaxomab in Gastric Signet Cell Carcinoma - a Report of 2 Cases
ONCOLOGY RESEARCH AND TREATMENT. 2014; 37(11): 674-677. Article

Al-Batran Salah-Eddin, Pauligk Claudia, Homann Nils, Hartmann Joerg T., Moehler Markus, Probst Stephan, Rethwisch Volker, Stoehlmacher-Williams Jan, Prasnikar Nicole, Hollerbach Stephan, Bokemeyer Carsten, Mahlberg Rolf, Hofheinz Ralf D., Luley Kim, Kullmann Frank, Jaeger Elke
The feasibility of triple-drug chemotherapy combination in older adult patients with oesophagogastric cancer: A randomised trial of the Arbeitsgemeinschaft Internistische Onkologie (FLOT65+)
EUROPEAN JOURNAL OF CANCER. 2013; 49(4): 835-842. Article

Greten T. F., Malek N. P., Schmidt S., Arends J., Bartenstein P., Bechstein W., Bernatik T., Bitzer M., Chavan A., Dollinger M., Domagk D., Drognitz O., Duex M., Farkas S., Folprecht G., Galle P., Geissler M., Gerken G., Habermehl D., Helmberger T., Herfarth K., Hoffmann R. T., Holtmann M., Huppert P., Jakobs T., Keller M., Klempnauer J., Kolligs F., Koerber J., Lang H., Lehner F., Lordick F., Lubienski A., Manns M. P., Mahnken A., Moehler M., Moench C., Neuhaus P., Niederau C., Ocker M., Otto G., Pereira P., Pott G., Riemer J., Ringe K., Ritterbusch U., Rummeny E., Schirmacher P., Schlitt H. J., Schlottmann K., Schmitz V., Schuler A., Schulze-Bergkamen H., von Schweinitz D., Seehofer D., Sitter H., Strassburg C. P., Stroszczyński C., Strobel D., Tannapfel A., Trojan J., van Thiel I., Vogel A., Wacker F., Wedemeyer H., Wege H., Weinmann A., Wittekind C., Woermann B., Zech C. J.
Diagnosis of and Therapy for Hepatocellular Carcinoma

ZEITSCHRIFT FUR GASTROENTEROLOGIE. 2013; 51(11): 1269-1326. Article

Heinemann V, von Weikersthal Fischer L., Decker T., Kiani A., Verhling-Kaiser U., Al Batran S., Heintges T., Lerchenmueller C., Kahl C., Seipelt G., Kullmann F., Stauch M., Scheithauer W., Hielscher J., Scholz M., Mueller S., Schaefer B., Moehler M., Modest D. P., Jung A., Stintzing S.
Randomized comparison of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment of KRAS-wildtype metastatic colorectal cancer: The FIRE-3 trial (AIO KRK 0307)
ONKOLOGIE. 2013; 36: 104-104. Meeting Abstract

Heinrich Bernd, Goepfert Katrin, Delic Maike, Galle Peter R., Moehler Markus
Influence of the oncolytic parvovirus H-1, CTLA-4 antibody tremelimumab and cytostatic drugs on the human immune system in a human in vitro model of colorectal cancer cells
ONCOTARGETS AND THERAPY. 2013; 6: 1119-1127. Article

Hoehler T., von Wichert G., Schimanski C., Kanzler S., Moehler M. H., Hinke A., Seufferlein T., Siebler J., Hochhaus A., Arnold D., Hallek M., Hofheinz R., Hacker U. T.
Phase I/II trial of capecitabine and oxaliplatin in combination with bevacizumab and imatinib in patients with metastatic colorectal cancer: AIO KRK 0205
BRITISH JOURNAL OF CANCER. 2013; 109(6): 1408-1413. Article

Lordick Florian, Kang Yoon-Koo, Chung Hyun-Cheol, Salman Pamela, Oh Sang Cheul, Bodoky Gyoergy, Kurteva Galina, Volovat Constantin, Moiseyenko Vladimir M., Gorbunova Vera, Park Joon Oh, Sawaki Akira, Celik Ilhan, Goette Heiko, Melezinkova Helena, Moehler Markus
Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial
LANCET ONCOLOGY. 2013; 14(6): 490-499. Article

Moehler M.
HOW TO DEVELOP MOLECULAR TARGETED DRUGS IN GASTRIC CANCER: FIRST OR SECOND LINE?
ANNALS OF ONCOLOGY. 2013; 24: 15-15. Meeting Abstract

Moehler M., Pech O., Hoffman A.
Early esophagogastric cancer. Diagnosis and treatment
ONKOLOGIE. 2013; 19(5): 354-+. Article

Moehler M., Thuss-Patience P., Schmoll H-J, Hegewisch-Becker S., Wilke H., Al-Batran S-E, Weissinger F., Kullmann F., von Weikerstahl Fischer L., Siveke J. T., Kanzler S., Schimanski C. C., Otte M., Schollenberger L., Koenig J., Galle P. R.
Na-Folfiri plus sunitinib versus Na-Folfiri alone in advanced chemorefractory esophagogastric cancer patients: A randomized double-blinded placebo-controlled multicentric AIO phase II trial
ONKOLOGIE. 2013; 36: 74-74. Meeting Abstract

Moehler Markus, Gockel Ines, Roessler Hans-Peter, Arnold Dirk, Trarbach Tanja, Thomaidis Thomas, Klautke Gunther, Roedel Claus, Brenner Baruch, Lang Hauke, Galle Peter R., Schimanski Carl C., Schmidberger Heinz
Prospective, open, multi-centre phase I/II trial to assess safety and efficacy of neoadjuvant radiochemotherapy with docetaxel and oxaliplatin in patients with adenocarcinoma of the oesophagogastric junction
BMC CANCER. 2013; 13. Article

Paoletti Xavier, Oba Koji, Bang Yung-Jue, Bleiberg Harry, Boku Narikazu, Bouche Olivier, Catalano Paul, Fuse Nozomu, Michiels Stefan, Moehler Markus, Morita Satoshi, Ohashi Yasuo, Ohtsu Atsushi, Roth Arnaud, Rougier Philippe, Sakamoto Junichi, Sargent Daniel, Sasako Mitsuru, Shitara Kohei, Thuss-Patience Peter, Van Cutsem Eric, Burzykowski Tomasz, Buyse Marc
Progression-Free Survival as a Surrogate for Overall Survival in Advanced/Recurrent Gastric Cancer Trials: A Meta-Analysis
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE. 2013; 105(21): 1667-1670. Article

Sieben Maiké, Schaefer Petra, Dinsart Christiane, Galle Peter R., Moehler Markus
Activation of the human immune system via toll-like receptors by the oncolytic parvovirus H-1
INTERNATIONAL JOURNAL OF CANCER. 2013; 132(11): 2548-2556. Article

Thomaidis Thomas, Goetz Martin, Gregor Sebastian Paul, Hoffman Arthur, Kouroumalis Elias, Moehler Markus, Galle Peter Robert, Schwarting Andreas, Kiesslich Ralf
Irritable bowel syndrome and organic diseases: A comparative analysis of esophageal motility
WORLD JOURNAL OF GASTROENTEROLOGY. 2013; 19(38): 6408-6415. Article

Wehler Thomas C., Graf Claudine, Moehler Markus, Herzog Jutta, Berger Martin R., Gockel Ines, Lang Hauke, Theobald Matthias, Galle Peter R., Schimanski Carl C.
Cetuximab-induced skin exanthema: prophylactic and reactive skin therapy are equally effective
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY. 2013; 139(10): 1667-1672. Article

Wehler Thomas C., Hamdi Swaantje, Maderer Annett, Graf Claudine, Gockel Ines, Schmidtman Irene, Hainz Michael, Berger Martin R., Theobald Matthias, Galle Peter R., Moehler Markus, Schimanski Carl C.
Single-agent therapy with sorafenib or 5-FU is equally effective in human colorectal cancer xenograft-
no benefit of combination therapy
INTERNATIONAL JOURNAL OF COLORECTAL DISEASE. 2013; 28(3): 385-398. Article

Ganser Christopher, Laueremann Eva, Maderer Annett, Stauder Torsten, Kramb Jan-Peter, Plutizki Stanislav, Kindler Thomas, Moehler Markus, Dannhardt Gerd
Novel 3-Azaindoly-4-arylmaleimides Exhibiting Potent Antiangiogenic Efficacy, Protein Kinase Inhibition, and Antiproliferative Activity
JOURNAL OF MEDICINAL CHEMISTRY. 2012; 55(22): 9531-9540. Article

Grenacher L., Schwarz M., Lordick F., Krause B., Roecken C., Moenig S., Ebert M., Jenssen C., Kauczor H. -U., Moehler M.
S3 Guideline - Diagnosis and Treatment of Gastric Carcinoma: Relevance for Radio logic Imaging
ROFO-FORTSCHRITTE AUF DEM GEBIET DER RONTGENSTRAHLEN UND DER BILDGEBENDEN VERFAHREN. 2012; 184(8): 706-712. Review

Harder J, Ihorst G, Heinemann V, Hofheinz R, Moehler M, Buechler P, Kloepfel G, Rocken C, Bitzer M, Boeck S, Endlicher E, Reinacher-Schick A, Schmoor C, Geissler M
Multicentre phase II trial of trastuzumab and capecitabine in patients with HER2 overexpressing metastatic pancreatic cancer
BRITISH JOURNAL OF CANCER. 2012; 106(6): 1033-1038. Article

Hoetker Michael S., Kiesslich Ralf, Diken Mustafa, Moehler Markus, Galle Peter R., Li Yanqing, Goetz Martin

Molecular in vivo imaging of gastric cancer in a human-murine xenograft model: targeting epidermal growth factor receptor

GASTROINTESTINAL ENDOSCOPY. 2012; 76(3): 612-620. Article

Hoetker MS, Kiesslich R, Diken M, Moehler M, Galle PR, Li YQ, Goetz M

Molecular Endomicroscopy for Diagnosis of Gastric Cancer: Targeting Epidermal Growth Factor Receptor (EGFR)

GASTROINTESTINAL ENDOSCOPY. 2012; 75(4): 215-215. Meeting Abstract

Hofheinz RD, Wenz F, Post S, Matzdorff A, Laechelt S, Hartmann JT, Muller L, Link H, Moehler M, Kettner E, Fritz E, Hieber U, Lindemann HW, Grunewald M, Kremers S, Constantin C, Hipp M, Hartung G, Gencer D, Kienle P, Burkholder I, Hochhaus A

Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial

LANCET ONCOLOGY. 2012; 13(6): -. Article

Kiesslich R., Moehler M., Hansen T., Galle P. R., Lang H., Gockel I.

Diagnosis and treatment of esophageal cancer

INTERNIST. 2012; 53(11): 1315-1327. Article

Lutz Manfred P., Zalberg John R., Ducreux Michel, Ajani Jaffer A., Allum William, Aust Daniela, Bang Yung-Jue, Cascinu Stefano, Hoelscher Arnulf, Jankowski Janusz, Jansen Edwin P. M., Kiesslich Ralf, Lordick Florian, Mariette Christophe, Moehler Markus, Oyama Tsuneo, Roth Arnaud, Rueschoff Josef, Ruhstaller Thomas, Seruca Raquel, Stahl Michael, Sterzing Florian, van Cutsem Eric, van der Gaast Ate, van Lanschot Jan, Ychou Marc, Otto Florian

Highlights of the EORTC St. Gallen International Expert Consensus on the primary therapy of gastric, gastroesophageal and oesophageal cancer - Differential treatment strategies for subtypes of early gastroesophageal cancer

EUROPEAN JOURNAL OF CANCER. 2012; 48(16): 2941-2953. Article

Meyer H. -J., Hoelscher A. H., Lordick F., Messmann H., Moenig S., Schumacher C., Stahl M., Wilke H., Moehler M.

Current S3 guidelines on surgical treatment of gastric carcinoma

CHIRURG. 2012; 83(1): 31-37. Article

Moehler M

Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial

Lancet Oncology. 2012; 13(12): 1225-1233

Moehler M., Maderer A., Khillimberger K., Galle P. R., Kindler T., Dannhardt G.

Aryl-heteroaryl-maleinimides - new selective inhibitors for treating gastrointestinal cancers

ONKOLOGIE. 2012; 35: 166-167. Meeting Abstract

Mueller A, Bachmann E, Linnig M, Khillimberger K, Schimanski CC, Galle PR, Moehler M

Selective PI3K inhibition by BKM120 and BEZ235 alone or in combination with chemotherapy in wild-type and mutated human gastrointestinal cancer cell lines

CANCER CHEMOTHERAPY AND PHARMACOLOGY. 2012; 69(6): 1601-1615. Article

Schimanski C. C., Moehler M., Lang H., Smith-Machnow V, Kanzler S., Hegewisch-Becker S., Doerfel S., Seehofer D., Bechstein W. O., Heike M., Overkamp F., Kullmann F., Voehringer M., Heinemann V, von Wichert G., Kasper S., Greil R., Schroeder J., Galle P. R., Schoen M.

A randomized, double-blind, placebo-controlled, multicenter, multinational, phase II trial of immunotherapy with L-BLP25 in patients with colorectal carcinoma following R0/R1 hepatic metastasectomy

ONKOLOGIE. 2012; 35: 57-57. Meeting Abstract

Schimanski Carl Christoph, Moehler Markus, Schoen Michael, van Cutsem Eric, Greil Richard, Bechstein Wolf Otto, Hegewisch-Becker Susanna, von Wichert Goetz, Voehringer Matthias, Heike Michael, Heinemann Volker, Peeters Marc, Kanzler Stephan, Kasper Stefan, Overkamp Friedrich, Schroeder Jan, Seehofer Daniel, Kullmann Frank, Linz Bernhard, Schmidtmann Irene, Smith-Machnow Victoria, Gockel Ines, Lang Hauke, Galle Peter R.

LICC: L-BLP25 in patients with colorectal carcinoma after curative resection of hepatic metastases-a randomized, placebo-controlled, multicenter, multinational, double-blinded phase II trial

BMC CANCER. 2012; 12. Article

Schmalfeldt B, Seck K, Gonschior AK, Gilet H, Heiss M, Hennig M, Moehler M, Schulze E, Wimberger P, Parsons SL

Quality of life in patients with malignant ascites and after treatment with catumaxomab: results from a phase II/III study comparing paracentesis plus catumaxomab with paracentesis alone

GEBURTSHILFE UND FRAUENHEILKUNDE. 2012; 72(4): -. Meeting Abstract

Sgourakis George, Gockel Ines, Karaliotas Constantine, Moehler Markus, Schimanski Carl Christoph, Schmidberger Heinz, Junginger Theodor

Survival after chemotherapy and/or radiotherapy versus self-expanding metal stent insertion in the setting of inoperable esophageal cancer: a case-control study

BMC CANCER. 2012; 12. Article

Van Cutsem E, Tejpar S, Vanbeckevoort D, Peeters M, Humblet Y, Gelderblom H, Vermorken JB, Viret F, Glimelius B, Gallerani E, Hendlisz A, Cats A, Moehler M, Sagaert X, Vlassak S, Schlichting M, Ciardiello F

Inpatient Cetuximab Dose Escalation in Metastatic Colorectal Cancer According to the Grade of Early Skin Reactions: The Randomized EVEREST Study

JOURNAL OF CLINICAL ONCOLOGY. 2012; 30(23): 2861-2868. Article

Wehler Thomas C., Cao Yang, Galle Peter R., Theobald Matthias, Moehler Markus, Schimanski Carl C. Combination therapies with oxaliplatin and oral capecitabine or intravenous 5-FU show similar toxicity profiles in gastrointestinal carcinoma patients if hand-food syndrome prophylaxis is performed continuously

ONCOLOGY LETTERS. 2012; 3(6): 1191-1194. Article

Werutsky G, Ducreux M, Lutz M, Mauer M, Van Cutsem E, Ruers T, Folprecht G, Moehler M, Aust D, Van Laethem JL, Lordick F, Nordlinger B, Roth A

The EORTC Gastrointestinal Tract Cancer Group: 50 years of research contributing to improved gastrointestinal cancer management

EJC SUPPLEMENTS. 2012; 10(1): 51-57. Article

Wimberger P., Gilet H., Gonschior A-K., Heiss M. M., Moehler M., Oskay-Oezcelik G., Al-Batran S-E., Schmalfeldt B., Schmittel A., Schulze E., Parsons S. L.

Deterioration in quality of life (QoL) in patients with malignant ascites: results from a phase II/III study comparing paracentesis plus catumaxomab with paracentesis alone
ANNALS OF ONCOLOGY. 2012; 23(8): 1979-1985. Article

Gonschior A, Gilet H, Heiss MM, Hennig M, Moehler M, Schmalfeldt B, Schulze E, Wimberger P, Parsons SL

Quality of Life in Patients With Malignant Ascites and Ascites Symptoms After Treatment With Catumaxomab: Results From a Multicenter Phase II/III Study Comparing Paracentesis Plus Catumaxomab With Paracentesis Alone
EUROPEAN JOURNAL OF CANCER. 2011; 47: S223-S223. Meeting Abstract

Heinrich S, Pestalozzi B, Lesurtel M, Berrevoet F, Laurent S, Delpero JR, Raoul JL, Bachellier P, Dufour P, Moehler M, Weber A, Lang HK, Rogiers X, Clavien PA

Adjuvant gemcitabine versus NEOadjuvant gemcitabine/oxaliplatin plus adjuvant gemcitabine in resectable pancreatic cancer: a randomized multicenter phase III study (NEOPAC study)
BMC CANCER. 2011; 11: -. Article

Hoffman A, Rahman F, Prengel S, Schuchmann M, Goetz M, Moehler M, Galle PR, Li Z, Kalloo AN, Kiesslich R

Mini-laparoscopy in the endoscop unit: Safety and outcomes in over thousand patients
World J Gastrointest Endosc. 2011; 3(1): 6-10

Hofheinz RD, Wenz F, Post S, Matzdorff A, Laechelt S, Hartmann JT, Muller L, Link H, Moehler M, Kettner E, Fritz E, Hieber U, Lindemann HW, Grunewald M, Kremers S, Constantin C, Hipp M, Gencer D, Burkholder I, Hochhaus A

Capecitabine (Cape) versus 5-fluorouracil (5-FU)-based (neo-)adjuvant chemo-radiotherapy (CRT) for locally advanced rectal cancer (LARC): Long-term results of a randomized, phase III trial
ONKOLOGIE. 2011; 34: 199-199. Meeting Abstract

Moehler M, Al-Batran SE, Andus T, Anthuber M, Arends J, Arnold D, Aust D, Baier P, Baretton G, Bernhardt J, Boeing H, Bohle E, Bokemeyer C, Bornschein J, Budach W, Burmester E, Caca K, Diemer WA, Dietrich CF, Ebert M, Eickhoff A, Ell C, Fahlke J, Feussner H, Fietkau R, Fischbach W, Fleig W, Flentje M, Gabbert HE, Galle PR, Geissler M, Gockel I, Graeven U, Grenacher L, Gross S, Hartmann JT, Heike M, Heinemann V, Herbst B, Herrmann T, Hocht S, Hofheinz RD, Hofler H, Hohler T, Holscher AH, Horneber M, Hubner J, Izbicki JR, Jakobs R, Jenssen C, Kanzler S, Keller M, Kiesslich R, Klautke G, Korber J, Krause BJ, Kuhn C, Kullmann F, Lang H, Link H, Lordick F, Ludwig K, Lutz M, Mahlberg R, Malfertheiner P, Merkel S, Messmann H, Meyer HJ, Monig S, Piso P, Pistorius S, Porschen R, Rabenstein T, Reichardt P, Ridwelski K, Rocken C, Roetzer I, Rohr P, Schepp W, Schlag PM, Schmid RM, Schmidberger H, Schmiegel WH, Schmoll HJ, Schuch G, Schuhmacher C, Schutte K, Schwenk W, Selgrad M, Sandler A, Seraphin J, Seufferlein T, Stahl M, Stein H, Stoll C, Stuschke M, Tannapfel A, Tholen R, Thuss-Patience P, Treml K, Vanhoefler U, Vieth M, Vogelsang H, Wagner D, Wedding U, Weimann A, Wilke H, Wittekind C

German S3-Guideline "Diagnosis and Treatment of Esophagogastric Cancer"
ZEITSCHRIFT FUR GASTROENTEROLOGIE. 2011; 49(4): 461-531. Article

Moehler M, Kanzler S, Schimanski CC, Worns MA, Denzer U, Kolligs F, Ebert M, Distelrath A, Zeuzem S, Lammert F, Geissler M, Lohse A, Dollinger M, Lindig U, Durr M, Lubomierski N, Kabisch M, Schadmand-Fischer S, Galle PR

A randomized, double-blind, multicenter phase II AIO trial with Gemcitabine plus Sorafenib versus Gemcitabine plus placebo in patients with chemo-naïve advanced or metastatic biliary tract cancer: first safety and efficacy data

ONKOLOGIE. 2011; 34: 217-217. Meeting Abstract

Moehler M, Mueller A, Hartmann JT, Ebert MP, Al-Batran SE, Reimer P, Weihrauch M, Lordick F, Trarbach T, Biesterfeld S, Kabisch M, Wachtlin D, Galle PR

An open-label, multicentre biomarker-oriented AIO phase II trial of sunitinib for patients with chemo-refractory advanced gastric cancer

EUROPEAN JOURNAL OF CANCER. 2011; 47(10): 1511-1520. Article

Moehler M, Mueller A, Trarbach T, Lordick F, Seufferlein T, Kubicka S, Geissler M, Schwarz S, Galle PR, Kanzler S

Cetuximab with irinotecan, folinic acid and 5-fluorouracil as first-line treatment in advanced gastroesophageal cancer: a prospective multi-center biomarker-oriented phase II study

ANNALS OF ONCOLOGY. 2011; 22(6): 1358-1366. Article

Moehler M, Muller A, Hartmann JT, Ebert M, Al-Batran SE, Reimer P, Weihrauch M, Lordick F, Trarbach T, Biesterfeld S, Kabisch M, Wachtlin D, Galle PR

An open-label, multicenter biomarker-oriented AIO phase II trial of sunitinib for patients with chemo-refractory advanced gastric cancer

ONKOLOGIE. 2011; 34: 103-103. Meeting Abstract

Moehler M, Muller A, Plutizki S, Khillimberger K, Galle PR, Dannhardt G

Moguntinones - new selective inhibitors for treating human gastrointestinal tumours

ONKOLOGIE. 2011; 34: 110-110. Meeting Abstract

Moehler M, Plutizki S, Khillimberger K, Galle PR, Dannhardt G, Mueller A

Moguntinones - New Selective Inhibitors for Treating Human Gastrointestinal Tumours

EUROPEAN JOURNAL OF CANCER. 2011; 47: S155-S155. Meeting Abstract

Moehler M, Schwarz S, Wagner AD

Esophagogastric Cancer: Integration of Targeted Therapies into Systemic Chemotherapy

CURRENT CANCER DRUG TARGETS. 2011; 11(6): 681-687. Review

Moehler M, Sieben M, Roth S, Springsguth F, Leuchs B, Zeidler M, Dinsart C, Rommelaere J, Galle PR
Activation of the human immune system by chemotherapeutic or targeted agents combined with the oncolytic parvovirus H-1

BMC CANCER. 2011; 11: -. Article

Moehler M, Voigt J, Kastor M, Heil M, Sengespeick C, Biesterfeld S, Dippold W, Kanzler S, Galle PR
Endoscopic ultrasonography-guided fine-needle aspiration (EUS-FNA) as primary diagnostic tool for unclear lesions in the upper gastrointestinal tract

DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT. 2011; 136(7): 303-308. Article

Schimanski CC, Jordan M, Schlaegel F, Schmidtman I, Lang H, Galle PR, Moehler M, Gockel I

SNP rs1801157 significantly correlates with distant metastasis in CXCL12 expressing esophagogastric cancer

INTERNATIONAL JOURNAL OF ONCOLOGY. 2011; 39(2): 515-520. Article

Schimanski CC, Moehler M, Gockel I, Zimmermann T, Lang H, Galle PR, Berger MR

Expression of chemokine receptor CCR5 correlates with the presence of hepatic molecular metastases in K-ras positive human colorectal cancer

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY. 2011; 137(7): 1139-1145. Article

Schimanski CC, Schlaegel F, Jordan M, Moehler M, Sgourakis G, Drescher DG, Galle PR, Lang H, Gockel I

VEGF-D Correlates with Metastatic Disease in Gastric Cancer Patients Undergoing Surgery

WORLD JOURNAL OF SURGERY. 2011; 35(5): 1010-1016. Article

Drescher D, Gockel I, Timm S, Berger MR, Herzer K, Schmidtman I, Junginger T, Galle PR, Lang H, Moehler M, Schimanski CC

Does Expression of Receptor Tyrosine Kinases in Gastric Adenocarcinoma Correlate with Clinicopathological Parameters?

HEPATO-GASTROENTEROLOGY. 2010; 57(98): 388-394. Article

Hohler T, Ruschoff J, Ridwelski K, Moehler M

HER2 Testing and Targeted Therapy in Advanced Gastric Cancer

ONKOLOGIE. 2010; 33: 26-30. Article

Kaechele V, Moehler M, Lutz MP, von Wichert G, Eisele M, Klaus J, Galle PR, Adler G, Seufferlein T

A phase I/II study of oxaliplatin and paclitaxel in patients with non-resectable cancer of the oesophagus and adenocarcinoma of the gastro-oesophageal junction: a study of the Arbeitsgemeinschaft Internistische Onkologie

CANCER CHEMOTHERAPY AND PHARMACOLOGY. 2010; 66(1): 191-195. Article

Lordick F, Grenacher L, Rocken C, Ebert M, Moehler M, Schumacher G

Diagnosis and treatment of gastric cancer

DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT. 2010; 135(34-35): 1671-1682. Review

Lyros O, Mueller A, Heidel F, Schimanski CC, Gockel I, Galle PR, Lang HK, Moehler M

Analysis of anti-proliferative and chemosensitizing effects of sunitinib on human esophagogastric cancer cells: synergistic interaction with vandetanib via inhibition of multi-receptor tyrosine kinase pathways

INTERNATIONAL JOURNAL OF CANCER. 2010; 127(5): 1197-1208. Article

Lyros O, Muller A, Heidel F, Schimanski CC, Gockel I, Galle PP, Lang H, Moehler M

Anti-proliferative and Chemo-sensitizing effect of Sunitinib on human Gastric cancer cell lines - Synergistic interaction with Vandetanib via the combined inhibition of Multireceptor Tyrosine kinase-Pathways.

ONKOLOGIE. 2010; 33: 150-150. Meeting Abstract

Moehler M, Ababneh Y, Verpoort K, Schmidt B, Musch R, Soeling U, Maintz C, Siebler J, Schimanski CC, Galle PR, Fahlke J

Efficacy and Safety of Irinotecan-Based Chemotherapy for Advanced Colorectal Cancer outside Clinical Trials: An Observational Study
ONKOLOGIE. 2010; 33(12): 684-690. Article

Moehler M, Kanzler S, Geissler M, Raedle J, Ebert MP, Daum S, Flieger D, Seufferlein T, Galle PR, Hoehler T
A randomized multicenter phase II study comparing capecitabine with irinotecan or cisplatin in metastatic adenocarcinoma of the stomach or esophagogastric junction
ANNALS OF ONCOLOGY. 2010; 21(1): 71-77. Article

Moehler M, Mueller A, Trarbach T, Lordick F, Seufferlein T, Kubicka S, Schwarz S, Galle PR, Kanzler S
Cetuximab with irinotecan, folinic acid and 5-fluorouracil as first-line treatment in advanced gastroesophageal cancer: A prospective multi-center biomarker-oriented phase II study
ONKOLOGIE. 2010; 33: 116-116. Meeting Abstract

Muller A, Linnig M, Neumann W, Galle PR, Moehler M
Double- and multi-targeting - new strategies of targeted agents in human colorectal cancer
ONKOLOGIE. 2010; 33: 65-65. Meeting Abstract

Schimanski C, Moehler M
Is sorafenib effective in colorectal cancer?
EJC SUPPLEMENTS. 2010; 8(7): 61-62. Meeting Abstract

Schimanski CC, Moehler M, Zimmermann T, Worns MA, Steinbach A, Baum M, Galle PR
Cetuximab-induced skin exanthema: Improvement by a reactive skin therapy
MOLECULAR MEDICINE REPORTS. 2010; 3(5): 789-793. Article

Schimanski CC, Zimmermann T, Schmidtman I, Gockel I, Lang HK, Galle PR, Moehler M, Berger MR
K-ras mutation status correlates with the expression of VEGFR1, VEGFR2, and PDGFR alpha in colorectal cancer
INTERNATIONAL JOURNAL OF COLORECTAL DISEASE. 2010; 25(2): 181-186. Article

Thuss-Patience P, Arnold D, Stein A, Grothe W, Seufferlein T, Reinacher-Schick A, Geissler M, Hofheinz R, Moehler M, Schmoll H
THE TEX REGIMEN (DOCETAXEL, OXALIPLATIN AND CAPECITABINE) IN PATIENTS WITH ADVANCED OR METASTATIC GASTRIC AND GASTROESOPHAGEAL CANCER: RESULTS FROM A PHASE II TRIAL OF THE GERMAN AIO GROUP
ANNALS OF ONCOLOGY. 2010; 21: 90-90. Meeting Abstract

Trarbach T, Moehler M, Heinemann V, Kohne CH, Przyborek M, Schulz C, Sneller V, Gallant G, Kanzler S
Phase II trial of mapatumumab, a fully human agonistic monoclonal antibody that targets and activates the tumour necrosis factor apoptosis-inducing ligand receptor-1 (TRAIL-R1), in patients with refractory colorectal cancer
BRITISH JOURNAL OF CANCER. 2010; 102(3): 506-512. Article

Zimmermann T, Moehler M, Gockel I, Sgourakis GG, Biesterfeld S, Muller M, Berger MR, Lang H, Galle PR, Schimanski CC

Low expression of chemokine receptor CCR5 in human colorectal cancer correlates with lymphatic dissemination and reduced CD8(+) T-cell infiltration
INTERNATIONAL JOURNAL OF COLORECTAL DISEASE. 2010; 25(4): 417-424. Article

Arnold D, Rummeny EJ, Kirchner T, Ridwelski K, Oettle H, Hartmann JT, Möhler M, Hölscher A, Lang H, Schlitt HJ, Neuhaus P
Diagnosis and treatment of liver metastases from primary colorectal tumour
Onkologie. 2009; 32(2): 7-12

Ebert MP, Auernhammer C, Caca K, Eckel F, Fischbach W, Geissler M, Göke B, Greten T, Kubicka S, Lutz MP, Möhler M, Opitz O, Pavel M, Porschen R, Reinacher-Schick A, Schmiegel W, Seufferlein T, Wiedenmann B, Schmid RM
Gastrointestinal oncology - therapy update 2008 / 2009
Z Gastroenterol. 2009; 47(3): 296-306

Gockel I, Domeyer M, Sgourakis GG, Schimanski CC, Moehler M, Kirkpatrick CJ, Lang H, Junginger T, Hansen T
Prediction model of lymph node metastasis in superficial esophageal adenocarcinoma and squamous cell cancer including D2-40 immunostaining.
J Surg Oncol. 2009; 100(3): 191-8

Hegewisch-Becker S, Vanhoefer U, Kubicka S, Pech M, Möhler M, Riess H, Hartmann JT, Malek N, Rödel C, Arnold D
Palliative treatment for colorectal cancer
Onkologie. 2009; 32(2): 13-6

Herzer K, Hofmann TG, Teufel A, Schimanski CC, Möhler M, Kanzler S, Schulze-Bergkamen H, Galle PR
IFN-alpha-induced apoptosis in hepatocellular carcinoma involves promyelocytic leukemia protein and TRAIL independently of p53
Cancer Res. 2009; 69(3): 855-62

Hofheinz RD, Wenz F, Lukan N, Mai S, Kripp M, Staiger W, Schwarzbach M, Willeke F, Möhler M, Post S, Hochhaus A
Oxaliplatin and capecitabine-based chemoradiotherapy for gastric cancer-an extended phase I MARGIT and AIO trial
Int J Radiat Oncol Biol Phys. 2009; 73(1): 142-7

Kanzler S, Trarbach T, Seufferlein T, Kubicka S, Lordick F, Geissler M, Daum S, Galle PR, Moehler M
Cetuximab with irinotecan/folinic acid/5-FU as first-line treatment in advanced gastric cancer: A nonrandomized multicenter AIO phase II study
JOURNAL OF CLINICAL ONCOLOGY. 2009; 27(15): -. Meeting Abstract

Lorenzen S, Schuster T, Porschen R, Al-Batran SE, Hofheinz R, Thuss-Patience P, Möhler M, Grabowski P, Arnold D, Greten T, Müller L, Röthling N, Peschel C, Langer R, Lordick F
Cetuximab plus cisplatin-5-fluorouracil versus cisplatin-5-fluorouracil alone in first-line metastatic squamous cell carcinoma of the esophagus: a randomized phase II study of the Arbeitsgemeinschaft Internistische Onkologie
Ann Oncol. 2009; 20(10): 1667

Lyros O, Mueller A, Heidel F, Schimanski CC, Gockel I, Galle PR, Lang H, Moehler M
Analysis of anti-proliferative and chemosensitizing effects of sunitinib on human esophagogastric cancer interaction with vandetanib via inhibition of multi-receptor tyrosine kinase pathways
Int J Cancer Dec 28. 2009; 1

Moehler M, Sprinzl MF, Abdelfattah M, Schimanski CC, Adami B, Godderz W, Majer K, Flieger D, Teufel A, Siebler J, Hoehler T, Galle PR, Kanzler S
Capecitabine and irinotecan with and without bevacizumab for advanced colorectal cancer patients
World J Gastroenterol. 2009; 15(4): 449-56

Moehler M, Trarbach T, Seufferlein T, Kubicka S, Lordick F, Geissler M, Daum S, Siebler J, Galle P, Kanzler S
CETUXIMAB WITH IRINOTECAN/FOLINIC ACID/5-FU AS FIRST-LINE TREATMENT IN ADVANCED GASTRIC CANCER: A NON-RANDOMISED MULTI-CENTER AID PHASE II STUDY
ANNALS OF ONCOLOGY. 2009; 20: 25-25. Meeting Abstract

Mueller A, Schwarz S, Biesterfeld S, Kanzler S, Trarbach T, Seufferlein T, Kubicka S, Lordick F, Galle PR, Moehler M
Cetuximab with irinotecan/folinic acid/5-FU as first-line treatment in advanced gastric cancer: A prospective multi-center phase II study and its molecular markers of the Arbeitsgemeinschaft Internistische Onkologie
EJC SUPPLEMENTS. 2009; 7(4): 25-25. Meeting Abstract

Schimanski CC, Frerichs K, Rahman F, Berger M, Lang H, Galle PR, Möhler M, Gockel I
High miR-196a levels promote the oncogenic phenotype of colorectal cancer cells.
World J Gastroenterol. 2009; 15(17): 2089-96

Schuetz K, Moehler M, Kettner E, Hegewisch-Becker S, Goekkurt E, Al-Batran S, Steffens C, Ehninger G, Stoehlmacher J
Results of a multi-center phase II study of imatinib and fluorouracil/leucovorin (FU/LV) in patients with unresectable or metastatic gallbladder or biliary tract cancer
EJC SUPPLEMENTS. 2009; 7(2): 395-395. Meeting Abstract

Schulze-Bergkamen H, Weinmann A, Moehler M, Siebler J, Galle PR
Novel ways to sensitise gastrointestinal cancer to apoptosis
Gut. 2009; 58(7): 1010-24

Wagner AD, Buechner-Steudel P, Moehler M, Schmalenberg H, Behrens R, Fahlke J, Wein A, Behl S, Kuss O, Kleber G, Fleig WE
Gemcitabine, oxaliplatin and 5-FU in advanced bile duct and gallbladder carcinoma: two parallel, multicentre phase-II trials
BRITISH JOURNAL OF CANCER. 2009; 101(11): 1846-1852. Article

Wagner AD, Möhler M
Development of target therapies in advanced gastric cancer: promising exploratory steps in a new era
Curr Opin Oncol. 2009; 21(4): 381-5

Borschitz T, Wachtlin D, Moehler M, Schmidberger H, Junginger T

Neoadjuvant chemoradiation and local excision of T2-3 rectal cancer
Ann Surg Oncol. 2008; 15(3): 712-720

Gockel I, Moehler M, Frerichs K, Drescher D, Trinh TT, Duenschede F, Borschitz T, Schimanski K, Biesterfeld S, Herzer K, Galle PR, Lang H, Junginger T, Schimanski CC
Co-expression of receptor tyrosine kinases in esophageal adenocarcinoma and squamous cell cancer.
Oncol Rep. 2008; 20: 845-850

Holtmann M, Domagk D, Weber M, Möhler M, Pott G, Ramadori G, Domschke W, Galle PR
Gastroenterological palliative care
Z Gastroenterol. 2008; 46(7): 712-24

Möhler M, Frings C, Müller A, Gockel I, Schimanski C, Biesterfeld S, Galle PR, Holtmann M
Expression analysis of EGFR, VEGF-C, VEGF-D and VEGFR3, demonstrates that VEGF-D expression correlates with human colorectal cancer aggressiveness and is downregulated by cetuximab
World J Gastroenterol. 2008; 14(26): 4156-67

Möhler M, Lyros O, Gockel I, Galle PR, Lang H
Multidisciplinary management of gastric and gastroesophageal cancers
World J Gastroenterol. 2008; 14(24): 3773-80

Möhler M, Ridwelski K, Karthaus M, Staib L, Knöfel WT, Kneba M, Schlitt HJ, Arnold D, Tannapfel A, Reinacher-Schick A, Piso P
Treatment of nonresectable liver metastases
Onkologie. 2008; 31(5): 14-8

Schimanski CC, Galle PR, Möhler M
Chemokine receptor CXCR4-prognostic factor for gastrointestinal tumors
World J Gastroenterol. 2008; 14(30): 4721-4

Schlitt HJ, Arnold D, Knöfel WT, Ridwelski K, Möhler M, Tannapfel A, Reinacher-Schick A
Surgical and perioperative therapy of liver metastases
Onkologie. 2008; 31(5): 9-13

Schulze-Bergkamen H, Ehrenberg R, Hickmann L, Vick B, Urbanik T, Schimanski CC, Berger MR, Schad A, Weber A, Heeger S, Galle PR, Moehler M
Bcl-x(L) and Myeloid cell leukaemia-1 contribute to apoptosis resistance of colorectal cancer cells
World J Gastroenterol. 2008; 14(24): 3829-3840

Sieben M, Herzer K, Zeidler M, Hörner V, Heinrichs V, Leuchs B, Schuler M, Cornelis JJ, Galle PR, Rommelaere J, Möhler M
Killing of p53-deficient hepatoma cells by parvovirus H-1 and chemotherapeutics requires promyelocytic leukemia protein.
World J Gastroenterol. 2008; 14(24): 3819-29

Sprinzi MF, Wytopil SM, Dahmen A, Kanzler S, Galle PR, Möhler M
Docetaxel as Salvage Therapy in Highly Pretreated and Drug Resistant Gastrointestinal Carcinomas.
Oncology. 2008; (2): 555-61

Wehler TC, Frerichs K, Graf C, Drescher D, Schimanski K, Biesterfeld S, Berger MR, Kanzler S, Junginger T, Galle PR, Moehler M, Gockel I, Schimanski CC
PDGFRalpha/beta expression correlates with the metastatic behavior of human colorectal cancer: a possible rationale for a molecular targeting strategy
Oncol Rep. 2008; 19: 697-704

Wehler TC, Graf C, Biesterfeld S, Brenner W, Schadt J, Gockel I, Berger MR, Thüroff JW, Galle PR, Moehler M, Schimanski CC
Strong expression of chemokine receptor CXCR4 by renal cell carcinoma correlates with advanced Disease
J Oncol. 2008: 10.1155/626340

Drescher D, Moehler M, Gockel I, Frerichs K, Muller A, Dunschede F, Borschitz T, Biesterfeld S, Holtmann M, Wehler T, Teufel A, Herzer K, Fischer T, Berger MR, Junginger T, Galle PR, Schimanski CC
Coexpression of receptor-tyrosine-kinases in gastric adenocarcinoma-a rationale for a molecular targeting strategy?
World J Gastroenterol. 2007; 13(26): 3605-9

Gockel I, Schimanski CC, Moehler M, Junginger T
Novel therapeutic targets in esophageal cancer: impact of chemokine receptor CXCR4.
Future Oncol. 2007; 3(2): 119-22

Moehler M, Galle PR, Gockel I, Junginger T, Schmidberger H
The multidisciplinary management of gastrointestinal cancer. Multimodal treatment of gastric cancer.
Best Pract Res Clin Gastroenterol. 2007; 21(6): 965-81
Möhler M, Galle PR
Aktuelle Diagnostik und Therapie des Magenkarzinoms
Z Gastroenterol. 2007; 2(3): 17-32

Möhler M, Galle PR
Neoadjuvante, perioperative, adjuvante und palliative Chemotherapie des Magenkarzinoms
Ärztliches Journal Onkologie. 2007; 6: 34-39

Möhler M, Galle PR, Kiesslich R
Endosonography of the gastrointestinal tract
Chirurg. 2007; 78(5): 420-2 424-7

Wagner A, Büchner-Stedel P, Wein A, Schmalenberg H, Lindig U, Möhler M, Behrens R, Kleber G, Kuss O, Fleig W
Gemcitabine, oxaliplatin and weekly high-dose 5-FU as 24-h infusion in chemo-naïve patients with advanced or metastatic pancreatic adenocarcinoma: a multicenter phase II trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO).
Ann Oncol. 2007; 3(2): 82-7

Eickhoff A, Martin W, Hartmann D, Eickhoff JC, Möhler M, Galle PR, Riemann JF, Jakobs R
A phase I/II multicentric trial of gemcitabine and epirubicin in patients with advanced pancreatic carcinoma.
Br J Cancer. 2006; 94(11): 1572-4

Gockel I, Schimanski CC, Heinrich C, Wehler T, Frerichs K, Drescher D, von Langsdorff C, Domeyer M, Biesterfeld S, Galle PR, Junginger T, Möhler M
Expression of chemokine receptor CXCR4 in esophageal squamous cell and adenocarcinoma.
BMC Cancer. 2006; 6: 290

Schimanski CC, Bahre R, Gockel I, Junginger T, Simiantonaki N, Biesterfeld S, Achenbach T, Wehler T, Galle PR, Möhler M
Chemokine receptor CCR7 enhances intrahepatic and lymphatic dissemination of human hepatocellular cancer.
Oncol Rep. 2006; 16(1): 109-13

Schimanski CC, Bahre R, Gockel I, Muller A, Frerichs K, Horner V, Teufel A, Simiantonaki N, Biesterfeld S, Wehler T, Schuler M, Achenbach T, Junginger T, Galle PR, Möhler M
Dissemination of hepatocellular carcinoma is mediated via chemokine receptor CXCR4.
Br J Cancer. 2006; 95(2): 210-7

Schimanski CC, Horner V, Kanzler S, Galle PR, Möhler M
Immuntherapie des Kolorektalkarzinoms--aktueller Stand und Perspektiven.
Z Gastroenterol. 2006; 44(8): 673-81

Sprinzl MF, Schimanski CC, Möhler M, Schadmand-Fischer S, Galle PR, Kanzler S
Gemcitabine in combination with EGF-Receptor antibody (Cetuximab) as a treatment of cholangiocarcinoma: a case report.
BMC Cancer. 2006; 6: 190

Wehler T, Wolfert F, Schimanski CC, Gockel I, Herr W, Biesterfeld S, Seifert JK, Adwan H, Berger MR, Junginger T, Galle PR, Möhler M
Strong expression of chemokine receptor CXCR4 by pancreatic cancer correlates with advanced disease.
Oncol Rep. 2006; 16(6): 1159-64

Moehler M, Eimermacher A, Siebler J, Hohler T, Wein A, Menges M, Flieger D, Junginger T, Geer T, Gracien E, Galle PR, Heike M
Randomised phase II evaluation of irinotecan plus high-dose 5-fluorouracil and leucovorin (ILF) vs 5-fluorouracil, leucovorin, and etoposide (ELF) in untreated metastatic gastric cancer
BRITISH JOURNAL OF CANCER. 2005; 92(12): 2122-2128. Proceedings Paper

Moehler MH, Zeidler M, Wilsberg V, Cornelis JJ, Woelfel T, Rommelaere J, Galle PR, Heike M
Parvovirus H-1-induced tumor cell death enhances human immune response in vitro via increased phagocytosis, maturation, and cross-presentation by dendritic cells
HUMAN GENE THERAPY. 2005; 16(8): 996-1005. Article

Möhler M, Teufel A, Galle PR
New chemotherapeutic strategies in colorectal cancer.
Recent Results Cancer Res. 2005; 165: 250-9

Schimanski CC, Schwald S, Simiantonaki N, Jayasinghe C, Gonner U, Wilsberg V, Junginger T, Berger MR, Galle PR, Moehler M

Effect of chemokine receptors CXCR4 and CCR7 on the metastatic behavior of human colorectal cancer

CLINICAL CANCER RESEARCH. 2005; 11(5): 1743-1750. Article

Wasser K, Moehler T, Nosas-Garcia S, Rehm C, Bartl R, Goldschmidt H, Duber C, Kauczor HU, Delorme S

Correlation of MRI and histopathology of bone marrow in patients with multiple myeloma
ROFO-FORTSCHRITTE AUF DEM GEBIET DER RONTGENSTRAHLEN UND DER BILDGEBENDEN
VERFAHREN. 2005; 177(8): 1116-1122. Article

Kiesslich R, Kanzler S, Vieth M, Moehler M, Neidig J, Nadar BJT, Schilling D, Burg J, Nafe B, Neurath MF, Galle PR

Minimal change esophagitis: Prospective comparison of endoscopic and histological markers between patients with non-erosive reflux disease and normal controls using magnifying endoscopy
DIGESTIVE DISEASES. 2004; 22(2): 221-227. Article

Wasser K, Moehler T, Neben K, Nosas S, Heiss J, Goldschmidt H, Hillengass J, Duber C, Kauczor HU, Delorme S

Dynamic MRI of the bone marrow for monitoring multiple myeloma during treatment with thalidomide as monotherapy or in combination with CED chemotherapy
ROFO-FORTSCHRITTE AUF DEM GEBIET DER RONTGENSTRAHLEN UND DER BILDGEBENDEN
VERFAHREN. 2004; 176(9): 1285-1295. Article

Teufel A, Steinmann S, Siebler J, Zanke C, Hohl H, Adami B, Schroeder M, Klein O, Höhler T, Galle PR, Heike M, Moehler M.

Irinotecan plus folinic acid/continuous 5-fluorouracil as simplified bimonthly FOLFIRI regimen for first-line therapy of metastatic colorectal cancer.

BMC Cancer. 2004 Jul 20;4:38. doi: 10.1186/1471-2407-4-38. PMID: 15265233; PMCID: PMC497044.

Moehler M, Haas U, Siebler J, Schimanski C, Hertkorn C, Hoehler T, Galle PR, Heike M.

Weekly treatment with irinotecan, folinic acid and infusional 5-fluorouracil (ILF) in patients with advanced gastric cancer.

Anticancer Drugs. 2003 Sep;14(8):645-50. doi: 10.1097/00001813-200309000-00010. PMID: 14501387.

Moehler M, Hoffmann T, Zanke C, Hohl H, Burg H, Ehscheid P, Schwindt P, Adami B, Schroeder M, Klein O, Baldus M, Galle PR, Heike M.

Safety and efficacy of outpatient treatment with CPT-11 plus bolus folinic acid/5-fluorouracil as first-line chemotherapy for metastatic colorectal cancer.

Anticancer Drugs. 2003 Jan;14(1):79-85. doi: 10.1097/00001813-200301000-00011. PMID: 12544262.

Moehler M, Gutzler F, Steinmann S, Boehme M, Raeth U, Stremmel W, Galle PR, Rudi J.

Comparison of a 48-hour infusion of 5-fluorouracil without folinic acid with 24-hour folinic acid/5-fluorouracil in patients with metastatic colorectal cancer refractory to bolus folinic acid/5-fluorouracil. A prospective cohort study.

Chemotherapy. 2003 May;49(1-2):85-9. doi: 10.1159/000069778. PMID: 12714817.

Moehler M, Hoffmann T, Hildner K, Siebler J, Galle PR, Heike M.

Weekly oxaliplatin, high-dose folinic acid and 24h-5-fluorouracil (FUFOX) as salvage therapy in metastatic colorectal cancer patients pretreated with irinotecan and folinic acid/5-fluorouracil regimens.

Z Gastroenterol. 2002 Dec;40(12):957-64. doi: 10.1055/s-2002-36156. PMID: 12564419.

Moehler M, Blechacz B, Weiskopf N, Zeidler M, Stremmel W, Rommelaere J, Galle PR, Cornelis JJ. Effective infection, apoptotic cell killing and gene transfer of human hepatoma cells but not primary hepatocytes by parvovirus H1 and derived vectors.

Cancer Gene Ther. 2001 Mar;8(3):158-67. doi: 10.1038/sj.cgt.7700288. PMID: 11332986.

Mantaka P, Strauss AD, Strauss LG, Moehler M, Goldschmidt H, Oberdorfer F, Kontaxakis G, Van Kaick G.

Detection of treated liver metastases using fluorine-18-fluorodeoxyglucose (FDG) and positron emission tomography (PET).

Anticancer Res. 1999 Sep-Oct;19(5C):4443-50. PMID: 10650790.

Moehler M, Dimitrakopoulou-Strauss A, Gutzler F, Raeth U, Strauss LG, Stremmel W.

¹⁸F-labeled fluorouracil positron emission tomography and the prognoses of colorectal carcinoma patients with metastases to the liver treated with 5-fluorouracil.

Cancer. 1998 Jul 15;83(2):245-53. PMID: 9669806.